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Polymerases are enzymes used by all cellular and viral organisms to replicate 
their genomes.  The human immunodeficiency virus (HIV) polymerase, reverse 
transcriptase (RT), uses a single-stranded RNA template to create double-stranded 
DNA during the course of the viral life cycle.  Successful reverse transcription relies 
on the speed of catalysis and the ability of the enzyme to stay bound to the template 
during synthesis.  I demonstrate that both of these properties can be modulated by the 
presence of different divalent cations, fundamentally altering the behavior of HIV 
RT.  In the presence of 2 mM Mg2+, the HIV RT primer-template complex has a half-
life of 1.7±1.0 min, incorporating nucleotides at a maximum rate of 3.5 nucleotides 
(nt) per second (average speed 1.4±0.4 nt/sec).  Substituting 2 mM Mg2+ with 400 µM 
Zn2+ dramatically slows the speed of catalysis (maximum 0.1 nt/sec, average 
  
0.022±0.003 nt/sec) and promotes primer-template complexes that last hours (half-
life of 220±60 min).  These profound changes to the enzyme’s function critically 
inhibit reverse transcription, even in the presence of optimal concentrations of Mg2+. 
In addition to the cation composition during reverse transcription, previous studies 
have demonstrated that the sequence of the primer-template substrate can also affect 
the duration of a RT-primer-template complex.  In light of this discovery, I 
investigated the tendency of two Family A DNA polymerases, the Thermus aquaticus 
DNA polymerase (Taq pol) and the Klenow fragment from Escherichia coli DNA 
polymerase I (Klenow), to selectively and tightly bind primer-template complexes.  
Using Primer-Template Systematic Evolution of Ligands by Exponential Enrichment 
(PT SELEX), I determined that both Taq pol and Klenow tightly bind to sequences 
containing regions that match the initiation and melting domains of promoters for the 
structurally similar bacteriophage T7-like RNA polymerases.  This suggests a shared 
sequence preference that might be present in all Family A DNA polymerases, derived 
from a common ancestor.  I plan to exploit this primer-template binding preference to 










MODULATION OF HIV-1 REVERSE TRANSCRIPTASE AND FAMILY A DNA 













Dissertation submitted to the Faculty of the Graduate School of the  
University of Maryland, College Park, in partial fulfillment 
of the requirements for the degree of 

















Professor Jeffrey J. DeStefano, Chair 
Professor Anne E. Simon 
Professor James N. Culver 
Professor Eric O. Freed 






















© Copyright by 



















This dissertation is dedicated to my mother, father, sister, and brother-in-law whose 





When I applied to graduate school, I thought I knew what I was getting 
into:  hard work, sleepless nights, and mountains of stress.  What I couldn’t predict 
were the amazing people I would meet along the way, who have kept me smiling 
through what has been both the most difficult and rewarding experience of my life. 
First and foremost, I want to thank my advisor, Dr. Jeffrey DeStefano, for his 
time, encouragement, knowledge, and for providing me with the space to grow as an 
independent researcher.  Jeff's immense patience has made it possible for me to 
continue through the periods of failed experiments and disappointing data that 
sometimes accompany research.  In addition to discussing papers, grants, and data, 
I’ll miss talking to him about music, philosophy, and (especially) politics.  Joining his 
lab was one of the best decisions I've ever made. 
I would also like to express my gratitude to my committee members, Drs. 
Anne Simon, Eric Freed, Jim Culver, and Siba Samal, for their feedback, support, and 
constructive criticism throughout this entire process.  Your involvement has been 
invaluable. 
In addition to the faculty who have played a role in my academic career, the 
members of my lab have shaped the day-to-day tenor of my research life.  I can’t 
thank my previous lab mates enough for their guidance and friendship:  Deena Jacob, 
who helped me feel at home in the initially scary world of Real Science; Megan Lai, 




a billion laughs and even more assists reaching high shelves; Gauri Nair, my lab 
mother, for her advice, food, and friendship; Divya Gangaramani, for Hindi lessons, 
conference entertainment, and being a wonderful and kind friend (I swear, I’ll make 
those antibiotic stocks tomorrow.  Really, I totally will).  Of course, I can’t forget my 
current lab mate, honorary little brother, and prank war adversary Vasu Achuthan: 
I’m going to miss you, Guppy.  Thank you for making my last couple of years here so 
much fun. 
Outside of the lab, I’ve been fortunate to meet an amazing group of 
people.  To the former (and honorary) Pirate House roommates--Brian Kimble, 
Douglas Ishii, Erin (and Ben!) Anderson, and Ted Gibbons--you've kept me sane, or 
at least made me feel so by comparison.  Thank you for the TV nights, group 
Halloween costumes, strangely elaborate board games, laughter, naps, five-hour 
discussions on what constitutes the best sandwich, and overall amazing 
friendship.  Thanks as well to Jen Shipley, Susan Ochsner, and Shahnawaz Zaheer for 
countless meals, laughs, bad movie marathons, and general tomfoolery.  I’m so 
incredibly lucky to have met you all of you.  
A profound thank you to my parents, Bill and Ruth Fenstermacher, for always 
being supportive of my education.  Dad, I guess this is the time to confess: when I 
was a kid, I used to ask you random questions at dinner hoping that you’d be so 
distracted answering me that I wouldn’t have to finish my vegetables.  It worked, but 
I ended up accidentally learning a lot on along the way.  I still don’t understand what 




and that there's a solution to every problem, if you just think hard enough.  Mom, my 
fellow MBC chemistry alumna, thank you for giving me practice as a graduate 
student before I even knew such a thing existed—getting to hang out with you at 
work in the hospital pharmacy was secretly a pretty good approximation of research 
life: hard work, odd hours, no sun, unpronounceable chemicals, and the ever-present 
scent of alcohol.  You had a much snazzier lab coat though! 
And finally, thank you to my sister Ashley for blazing this Ph.D. path well 
before I did.  I’m sure I got asked, “When are you graduating?” only a third as many 
times as I would have otherwise.  You and your husband Rick have provided me with 
great advice, weekends away from the lab, jogging company, and—let’s be honest—





Table of Contents 
 
 
Dedication	  ..............................................................................................................................	  ii	  
Acknowledgements	  .............................................................................................................	  iii	  
Table of Contents	  .................................................................................................................	  vi	  
List of Tables	  .....................................................................................................................	  viii	  
List of Figures	  .......................................................................................................................	  ix	  
Chapter 1: HIV and RT	  ........................................................................................................	  1	  
1.1 HIV & AIDS	  ............................................................................................................................	  1	  
1.1.1 General history	  ................................................................................................................................	  1	  
1.1.2 Classification and diversity	  .........................................................................................................	  2	  
1.1.3 HIV clinical progression and AIDS	  .........................................................................................	  5	  
1.1.4 Treatments	  ........................................................................................................................................	  6	  
1.2 The Viral Lifecycle	  ...............................................................................................................	  11	  
1.2.1 HIV genome	  ..................................................................................................................................	  11	  
1.2.2 Transmission, lifecycle, and disease	  .....................................................................................	  16	  
1.2.3 Reverse Transcription	  ................................................................................................................	  20	  
Chapter 2: Mechanism of HIV reverse transcriptase inhibition by zinc: formation of a 
highly stable enzyme-primer-template complex with profoundly diminished catalytic 
activity	  .................................................................................................................................	  26	  
2.1 Introduction	  ............................................................................................................................	  26	  
2.2 Materials and Methods	  .........................................................................................................	  28	  
2.3 Results	  ....................................................................................................................................	  34	  
2.3.1 Zn2+ potently inhibits HIV-RT catalysis in the presence of Mg2+	  ..............................	  34	  
2.3.2 Zn2+ is a more potent inhibitor of HIV-RT than Ca2+ and Mn2	  ...................................	  38	  
2.3.3 Zn2+ supports the RNase H activity of HIV-RT at concentrations similar to those 
observed for nucleotide extension	  ....................................................................................................	  41	  
2.3.4 HIV-RT forms a very stable catalytically competent complex with primer-
template in the presence of Zn2+ that traverses the template slowly but can remain 
associated for hours	  ...............................................................................................................................	  47	  
2.3.5 Other viral RTs from AMV and MuLV as well as an RNase H minus HIV mutant 
(HIV-RTE478>Q) can also use Zn2+ for nucleotide incorporation	  .............................................	  52	  
2.4 Conclusions	  ............................................................................................................................	  54	  
Chapter 3: Tightly binding DNA aptamers against Family A DNA polymerases	  .....	  61	  
3.1 Introduction	  ............................................................................................................................	  61	  
3.1.1 SELEX and Aptamers	  ...............................................................................................................	  61	  
3.1.2 PT-SELEX against HIV RT	  ....................................................................................................	  67	  
3.1.3 Family A DNA polymerases	  ...................................................................................................	  69	  
3.2 Materials and Methods	  .........................................................................................................	  77	  
3.3 Results	  ....................................................................................................................................	  81	  
3.3.1 SELEX results for exo-Klenow	  ..............................................................................................	  81	  
3.3.2 Determination of sequences important for exo-Klenow binding	  .................................	  85	  




3.3.4 Determination of sequences important for Taq pol binding	  .........................................	  92	  
3.3.5 Enzyme specificity to selected sequences	  ...........................................................................	  96	  
3.4 Discussion	  ..............................................................................................................................	  96	  
3.5 Conclusions	  .........................................................................................................................	  101	  
Chapter 4: Modulation of Reverse Transcription in vivo	  ............................................	  104	  
4.1 The effect of cellular small molecules on reverse transcription	  ...................................	  104	  
4.1.1 Introduction	  .................................................................................................................................	  104	  
4.1.2 Materials and Methods	  ............................................................................................................	  105	  
4.1.3 Results and Discussion	  ............................................................................................................	  106	  
4.2 Inhibition of HIV replication in cell culture by aptamers against HIV RT	  ....................	  109	  
4.2.1 Introduction	  .................................................................................................................................	  109	  
4.2.2 Materials and methods	  .............................................................................................................	  112	  
4.2.3 Results	  ...........................................................................................................................................	  115	  
4.2.4 Discussion	  ....................................................................................................................................	  123	  
4.3 Conclusions	  .........................................................................................................................................	  123	  
Chapter 5: General Conclusions	  .....................................................................................	  125	  













List of Tables 
 
Table 1: Classes and examples of HIV ARVs. ............................................................. 9 
 
Table 2: Host and HIV-1 proteins necessary for the viral lifecycle. .......................... 15 
 
Table 3.  Selected aptamers in clinical trials for the treatment of disease. ................. 66 
 
Table 4. Binding affinities of various viral RTs for their PPT and SELEX products. 68 
 
Table 5. Kd of  Klenow for the Exo-Kl sequence and modified constructs. ............... 87 
 
Table 6.  Taq1 constructs generated for mutational analysis of the nucleotides 
important for Taq pol binding to primer-templates ............................................ 94 
 
Table 7. Taq2 constructs generated for mutational analysis of the nucleotides 
important for Taq pol binding to primer-templates ............................................ 95 
 
Table 8.  Consensus sequences for the promoters of the single-subunit RNA 




List of Figures 
 
Figure 1: An unrooted phylogenetic tree showing the relationships between simian 
immunodeficiency viruses (SIV) and the two species of HIV (HIV-1 and HIV-
2).. ......................................................................................................................... 3 
 
Figure 2:  The subtypes of HIV-1 group M .................................................................. 4 
 
Figure 3:  Organization of the HIV-1 provirus. .......................................................... 13 
 
Figure 4.  The life cycle of HIV.. ................................................................................ 17 
 
Figure 5:  A Mature HIV virion. ................................................................................. 19 
 
Figure 6. A crystal structure of HIV RT bound to dsDNA. ........................................ 21 
 
Figure 7.  Reverse transcription of the HIV genome. ................................................. 25 
 
Figure 8:  Reverse transcription with 2 mM Mg2+ and increasing Zn2+ concentrations.
............................................................................................................................. 36 
 
Figure 9: Inhibition of reverse transcription with 2 mM Mg2+ by increasing 
concentrations of Zn2+, Ca2+ and Mn2+. .............................................................. 39 
 
Figure 10: Reverse transcription with Zn2+ alone and various dNTP concentrations. 40 
 
Figure 11: Reverse transcription with various concentrations of Mg2+ and Mn2+. ..... 44 
 
Figure 12: RNase H digestion with HIV-RT in the presence of varying concentrations 
of Zn2+. ................................................................................................................ 45 
 
Figure 13: HIV-RT processivity with Mg2+ and Zn2+. ................................................ 49 
 
Figure 14: Plot of RT-primer-template complex binding stability in the presence of 
Mg2+, Mn2+, and Zn2+ .......................................................................................... 51 
 
Figure 15: Reverse transcription with various RTs in the presence of Zn2+. .............. 53 
 
Figure 16  Crystal structures of DNA polymerases bound to DNA ........................... 71 
 
Figure 17: Sequence similarity of the Family A DNA polymerases. ......................... 72 
 





Figure 19. The PT SELEX method used to generate aptamers against Klenow and 
Taq pol. ............................................................................................................... 76 
 
Figure 20. Gel shift comparison between the starting pool and round 7 pool from Exo-
Klenow SELEX. ................................................................................................. 83 
 
Figure 21. Primer-template sequences selected by Exo-Klenow SELEX. .................. 84 
 
Figure 22.  Gel shift with the Exo-Kl construct and a modified version, which has the 
T7Pcore replaced. ............................................................................................... 88 
 
Figure 23.  Sequences recovered from round seven of Taq pol PT SELEX. ............. 90 
 
Figure 24.  Gel shift of Taq1 and Taq2 constructs, as well as a random pool, by Taq 
pol ....................................................................................................................... 91 
 
Figure 25. HIV RT extension of a ssDNA template stimulated by SMF ................. 108 
 
Figure 26.  Structure of the nucleodendrimer ........................................................... 111 
 
Figure 27. Aptamers used to test inhibition of HIV replication in cell culture. ....... 113 
 
Figure 28. Inhibition of HIV replication by the thioaptamer .................................... 116 
 
Figure 29.  The effect of varying concentrations of dendrimers on HIV infection and 
cell growth in the presence and absence of thioaptamer.. ................................. 118 
 
Figure 30. Inhibition of HIV replication by the 2,4 O-methyl aptamer in the presence 
and absence of the dendrimer. .......................................................................... 120 
 




List of Abbreviations 
aa  -Amino acid(s) 
AIDS  -Acquired Immune Deficiency Syndrome 
AMV  -Avian myeloblastosis virus 
ARV  -Anti-retroviral 
bp  -Base pair(s) 
BSA  -Bovine serum albumin  
dNTPs  -Deoxyribonucleotide triphophates 
ds  -Double-stranded 
DTT  -Dithiothreitol 
EDTA  -Ethylenediaminetetraacetic acid 
exo  -Exonuclease 
HAART -Highly Active Anti-Retroviral Therapy 
HIV  -Human Immunodeficiency Virus 
hr  -Hour 
Kb  -Kilobase(s) 
Kd  -Dissociation constant 
kDa  -Kilo Daltons 
LTR  -Long terminal repeat 
Min  -Minutes 
MuLV  -Moloney murine leukemia virus 
nt  -Nucleotide(s) 




PCR  -Polymerase chain reaction 
PNK  -Polynucleotide kinase 
Pol  -Polymerase  
PPT  -Polypurine tract 
PR  -Protease 
PT  -Primer-template 
RNAP  -RNA polymerase 
RNase H -Ribonuclease H 
RT  -Reverse Transcriptase 
sec  -Second 
SELEX -Selective Enrichment of Ligands by Exponential Enrichment 
SMF  -Small Molecular Fraction 
SIV  -Simian Immunodeficiency Virus 
ss  -Single-stranded 




Chapter 1: HIV and RT 
1.1 HIV & AIDS 
1.1.1 General history 
During the late 1970s, doctors began to observe otherwise healthy patients 
suffering from diseases typically associated with immunocompromised individuals, 
such as transplant recipients (1, 2).  Initially seen only in the gay community, the 
syndrome was first called Gay Related Immune Deficiency (GRID).  However, new 
patient populations were soon discovered, such as blood transfusion recipients (3) and 
IV drug users (4), necessitating a more accurate name to encompass the full subset of 
individuals with symptoms:  Acquired Immune Deficiency Syndrome (AIDS).  Many 
theories were proposed to explain the disease, some of which included drug abuse, 
lifestyle factors, or an unknown pathogen.  In 1983, Françoise Barré-Sinoussi and 
Luc Montagnier’s group isolated the causative agent of AIDS from the lymph nodes 
of a patient and named it the Lymphadenopathy-Associated Virus (LAV) (5).  
Subsequently, Robert Gallo’s team purified and characterized the same virus, naming 
it Human T-cell Lymphotrophic Virus III (HTLV-III) (6).  Both groups share credit 
for the discovery of what was later renamed the Human Immunodeficiency Virus 
(HIV) and are responsible for determining that this novel complex retrovirus was 
responsible for the immune destruction that led to AIDS.  While a death sentence in 
the 1980s, decades of research have yielded multiple therapeutics, which allow most 
HIV patients to control their infections and achieve lifespans approaching normal.  




Currently, an estimated 35 million are infected worldwide (0.8% of the global adult 
population), of whom 2 million died in 2012 alone (7).  In countries that have 
promoted safe sex initiatives and have the infrastructure to provide treatment access, 
infection rates are tapering off.  However, many areas of the world are unable to 
provide adequate treatment or prophylactic information, resulting in infection rates 
approaching 25% of the adult population in some parts of Sub-Saharan Africa (7). 
1.1.2 Classification and diversity 
 HIV is a lentivirus (“slow virus”) of the family Retroviridae.  It is closely 
related to simian immunodeficiency virus (SIV), which infects many Old World 
primate species and is responsible for infections ranging from asymptomatic to 
causing AIDS-like illness.  HIV itself consists of two discrete viruses, HIV-1 and 
HIV-2, that share a 60% nucleotide sequence identity (8). HIV-1 is largely 
responsible for the global pandemic and is broken down into four groups:  M (major), 
O (outlier), N (non-M, non-O), and the most recently identified group P.  Groups M, 
N, and O are most closely related to strains of SIV from chimpanzees while group P 
is most similar to SIV from gorillas (Figure 1) (9).  Group M, which is responsible for 
>90% of all global HIV infections, can be further broken down into several subtypes, 
as well as intersubtype recombinants referred to as circulating recombinant forms 
(CRFs) (Figure 2) (10).  Globally, subtype C is the most prevalent but the 
predominant subtype varies by country (for instance, American and European HIV 
infections are primarily subtype B).  In contrast to HIV-1, HIV-2 is mostly limited to 
Central and West Africa and is likely derived from a zoonotic event with SIV from 





Figure 1: An unrooted phylogenetic tree showing the relationships between 
simian immunodeficiency viruses (SIV) and the two species of HIV (HIV-1 and 
HIV-2).  161 whole genome nucleotide sequences were acquired from the Los 
Alamos National Labs HIV Sequence Database curated web alignment and modeled 
using generalised time-reversible (GTR) paramaters in PhyML. The scale bar 
indicates the average number of substitutions per site for that branch length.  HIV-1 is 
most similar to SIV of great apes and consists of four groups that most likely result 
from independent transmission events from chimpanzees (M, N, & O) and gorillas 








Figure 2:  The subtypes of HIV-1 group M.  There are several group M subtypes, 
as well as circulating recombinant forms that are derived from two or more parent 
subtypes.  The percentage of group M infections by each subtype is included; an * 
indicates those accounting for <1% of all infections (12).  Subtype B is the most 






1.1.3 HIV clinical progression and AIDS 
The clinical progression of HIV infection is characterized by rising viral titers, 
CD4+ T-cell depletion, immune disregulation and collapse.   This process has roughly 
four phases (13):   
1. Infection and incubation: Transmission occurs mainly through three 
mechanisms: sexual contact, intravenously (through drug use or blood 
transfusion), and vertical transmission (during birth or through breast 
feeding).  The likelihood of transmission increases with higher viral 
titers in the blood and bodily fluids; patients on a successful anti-
retroviral regimen are significantly less likely to infect others.  During 
this period, which lasts two to four weeks, the typical tests performed 
by healthcare providers cannot detect HIV infection, although viral 
RNA and DNA might be assayable by qPCR. 
2. Acute viremia: The virus begins to proliferate rapidly, rendering the 
patient highly infectious.  Concurrently, CD4+ T-cell counts decrease 
as infected cells are killed (from a normal value of ~1200 cells/µl in 
circulating blood down to ~600 cells/µl).  This corresponds to immune 
suppression and, in some individuals, self-limiting flu-like symptoms.  
An adaptive immune response is mounted which depresses viral titers, 
although it cannot clear the infection entirely.  After one to four weeks, 
viral load decreases and CD4+ T-cell counts recover, but only to ~800 
cells/µl.  From this point, the most common clinical HIV test (anti-




3. Clinical latency: After the partial recovery of the immune system, 
CD4+ titers are maintained by accelerated production to account for 
virus-induced death.  The immune response continues to suppress HIV 
titers for a period of months to years and patients receiving treatment 
or rare patients with a resistant genetic profile (long-term non-
progressors) can maintain this stage indefinitely. However, without 
treatment, the CD4+ T-cell count steadily decreases and viral titers 
increase.   
4. AIDS: Eventually, the immune system decay reaches a critical point 
of collapse (usually when the CD4+ T-cell count is < 200 cells/µl) and 
individuals become susceptible to opportunistic infections, such as 
Kaposi’s sarcoma, Pneumocystic carinii pneumonia, some 
lymphomas, and other illnesses.  The CDC considers HIV+ individuals 
with one of these AIDS-defining conditions to have progressed to 
AIDS, whereas the WHO also requires a CD4+ T-cell count below 200 
cells/µl.  Without treatment, patients will succumb to one or more of 




In 1987, the FDA approved the first anti-retroviral (ARV) for treatment of 
HIV: zidovudine (AZT), which is a nucleoside-analog RT inhibitor (NRTI) (14).  




completely clear infection due to some integrated virus remaining in long-lived 
quiescent cells, which can reactivate at any time to produce more viruses.  Eventually, 
low levels of replicating virus permit drug-resistant mutants to flourish.  Since then, 
several new classes of drugs (see Table 1: Classes and examples of HIV ARVs.) have 
been developed (15) and treatment has evolved to the current drug regime, Highly 
Active Antiretroviral Therapy (HAART), which utilizes combinations of drugs to 
reduce the likelihood of resistance.  The general guidelines for HAART recommend 
two nucleoside-analog RT inhibitors and a third drug from a different class (for 
instance, a protease or integrase inhibitor).  In areas where drug-resistant mutants are 
common, the patients beginning treatment will have their baseline resistance 
measured to determine the susceptibility of their HIV to specific ARVs.  In cases 
where the HIV resistance profile is such that HAART fails to control infection, Mega-
HAART/salvage therapy (HAART+additional drug combinations) is the final line of 
defense. 
Early ARVs often had extremely unpleasant side effects, such as anemia, 
nausea, and vomiting.  Newer therapeutics often have fewer problems, but adverse 
reactions are still common and can decrease the quality of life for those taking them.  
As ARVs fail to completely clear HIV, patients must maintain these regimes 
indefinitely (16). 
An important factor in treating HIV infection is when to begin ARV therapy.  
Without ARVs, most patients will eventually progress to AIDS and develop 
opportunistic infections.  As immune suppression of the virus fails, they will also 




viremia and both preserves the immune system from HIV-related destruction and 
lowers the risk of transmission.  As any drug therapy creates a selective pressure for 
the enrichment of drug-resistant mutants relative to drug-susceptible viruses in the 
population, it is important to continue treatment one it is begun; cessation of 
treatment allows expansion of the viral pool, permitting new mutations and allowing 
the potential for recombination between partially- or fully-resistant viruses.  
Unfortunately, the unpleasant side effects associated with many ARVs can discourage 
compliance with a lifelong treatment regimen. 
For a time, brief drug ‘holidays’ (where the patient discontinued their 
medication for a short duration) were encouraged by doctors to improve the quality of 
life for HIV patients.  Ultimately, it was determined that these holidays increased the 
potential for drug resistance and the policy was discouraged.  While the current 
treatment guideline is to ‘treat early-treat hard’ (17), patients and their doctors must 
weigh the risk of transmission and the consequences of unchecked viremia against the 
potential side effects, cost, and willingness of the patient to continue therapy 
indefinitely once it is begun.  So far, there are no data to suggest that treating patients 
with CD4+ cell counts >350 cells/ul has benefits that outweigh the potential issues 
(16).  A clinical trial to address the risk:benefit ratio of beginning treatment in 






Class Target protein Function Example 
Nucleoside-analog 
RT inhibitors Reverse 
Transcriptase 








Integration inhibitor Integrase 
Blocks integration 
of viral DNA into 
the host genome 
Raltegravir 
Protease inhibitor Protease 
Prevents proteolytic 






cleavage of the Gag 




CCR5 Prevents binding of gp120 with CCR5 Maraviroc 
gp41 Prevents fusion with the membrane Enfuvirtide 





 In 2009, researchers announced the first known ‘cure’ of HIV in a man who 
became known as the Berlin Patient.  After infection, he had developed leukemia and 
required a bone marrow transplant.  His transplant came from a donor who had a 
CCR5Δ32 mutation, which results in a truncated CCR5 receptor; cells with this 
mutation are resistant to HIV infection (19).  Six years after transplant and cessation 
of HAART, the Berlin Patient continues to have undetectable levels of viral 
replication and is considered functionally cured.  Since then, two other cures were 
tentatively announced with a different protocol: conventional bone marrow transplant 
while continuing HAART (20).  Sadly, this treatment failed and the patients 
experienced a return of viremia (21). 
 The treatment used by the Berlin Patient was expensive, difficult to obtain, 
and, due to the bone marrow transplant, dangerous.  It is unlikely that this will ever be 
expanded into a global cure, although it does offer hope for treatments that utilize the 
resistance of CCR5Δ32 cells to infection.  Potential avenues of achieving this are 
under investigation; one method uses zinc finger nucleases to target CCR5, resulting 
in CCR5- cells that are resistant to HIV infection (22). 
Currently, the only way to prevent HIV transmission is through barriers 
(condoms or dental dams during sexual contact), avoidance (only using sterile 
needles, abstaining from unprotected sex, not breastfeeding if HIV+).  After exposure 
(such as during childbirth or following a contaminated needle stick), prophylactic 
ARV treatment can decrease the likelihood of contracting HIV.  Attempts to develop 




1.2 The Viral Lifecycle 
1.2.1 HIV genome  
 The diploid HIV genome packaged in the 80-100 nm virions is two 
synonymous copies of a ~9.3 kb single-stranded, positive-sense RNA.  As a complex 
retrovirus, it contains the canonical retroviral genes gag, pol, and env, but also 
encodes several regulatory and accessory proteins (Tat and Rev; Vpu, Vpr, Vif, and 
Nef, respectively) (see Table 2 and).  The gene products Gag, Pol, and Env are 
polyproteins.  While Env is produced from its own mRNA, Gag contains a frameshift 
signal which is read through by the ribosome ~5-10% of the time, producing Gag-Pol 
(23).  Pol is not synthesized independently.  The regulatory and accessory proteins are 
also produced from individually spliced mRNAs.  After reverse transcription and 
integration, the now 9.7 kb dsDNA genome is referred to as the provirus.  
 In addition to genes, the genome also contains several features that are 
essential to viral replication.  These include:   
In the RNA genome, each end is flanked by a unique region (termed U5 or U3 
for the 5′ and 3′ ends of the genome, respectively) and a repeated region (R).  During 
reverse transcription into proviral DNA, the U5 and U3 regions are duplicated to the 
opposite side of the genome, leaving each end of the provirus flanked with a U3-R-
U5 sequence called the Long Terminal Repeat (LTR).  The LTRs are important for 
both complete genome reverse transcription (1.2.3 Reverse Transcription) and mRNA 
transcription).  From 5′ to 3′, the 5′ LTR contains: 




o A primer-binding site for a packaged host tRNAlys, used as a primer 
for ssDNA synthesis.  
o The Psi element and dimer initiation site, which are necessary for co-
packaging of the two copies of the RNA genome.  
• The Rev response element (RRE), which is the Rev binding site.   
• Two polypurine tracts (PPTs), which are used for plus-strand DNA synthesis 
priming (see section 1.2.3 Reverse Transcription). 







Figure 3:  Organization of the HIV-1 provirus. The 9.7 kb provirus has the same 
gene arrangement as the 9.1 kb RNA genome but is slightly larger due to the U3/U5 









Expressed on the surface of some components of the 
immune system (CD4+ T-cells, macrophages, & 




receptor type 5 




receptor type 4 
N/A Expressed on the surface of many cell types, including leukocytes, acts as a co-receptor for HIV binding 
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1.2.2 Transmission, lifecycle, and disease 
The viral life cycle is illustrated in Figure 4.  HIV requires a CD4 receptor for 
entry, limiting infection to CD4+ components of the immune system: T-cell 
lymphocytes and monocytes such as macrophages.  A secondary entry requirement is 
a co-receptor such as the chemokine receptors CCR5 or CXCR4.  Viruses that require 
CCR5 are considered R5-tropic, while CXCR4-requiring viruses are X4-tropic.  
Dual-tropism (R5/X4) and other rare receptor preferences also exist.  The viral 
envelope protein gp120 docks with CD4 and then undergoes a conformational 
change, exposing regions that bind to the co-receptor, which allows gp41 to induce 








Figure 4.  The life cycle of HIV.  HIV infects CD4+ cells, where it reverse 
transcribes its genome from ssRNA to dsDNA and integrates this into the host 
chromosome.  By using cellular machinery, it synthesizes proteins and RNA genomes 





After fusion, the viral capsid containing the genomic RNA is injected into the 
host cell.  Progressive uncoating allows packaged RT to initiate reverse transcription 
and convert the single-stranded diploid RNA genome into double stranded DNA (see 
section 1.2.3 Reverse Transcription).  The newly synthesized DNA, RT, IN, and Vpr, 
form the pre-integration complex that is transported to the nucleus.  Lentiviruses, 
unlike simple retroviruses, can infect both dividing and non-dividing cells by entering 
through a nuclear pore complex.  Once inside, IN removes the terminal two 3′ 
nucleotides from each strand, exposing the 3′ hydroxyl on the conserved terminal CA 
nucleotide pair.  Integrase inserts these exposed ends into the host genome and the 
gaps are repaired by host cellular machinery, resulting in a permanent, covalently 
integrated provirus (24).    
After integration, HIV relies on host machinery to produce new viral RNA for 
protein production and new genomes for nascent viral particles.  Initially, the two 
LTRs act as weak promoters to induce RNA pol II to transcribe spliced viral mRNA.  
However, as viral proteins are synthesized, Tat is imported into the nucleus and 
recruits a transcription complex to the TAR that increases viral mRNA output.  Later, 
Rev is also imported and, by binding the RRE, depresses splicing and allows export 
of full-length genomic RNA.  Two copies of this viral RNA dimerize using the DIS 
and are bound by Gag at the Psi element for packaging into the nascent viral particles.  
If a cell is co-infected by two HIV viruses, it’s possible for Gag to package an RNA 
from each parental sequence; the major requirement for co-packaging is a compatible 
DIS.  This allows for potential recombination during the next round of replication and 





Figure 5:  A Mature HIV virion. The diploid genomic RNA (white) is coated in 
nucleocapsid protein.  Integrase and reverse transcriptase are packaged within the 
virion, for converting the RNA genome to dsDNA and integrating it into the host 
genome.  The virion is enclosed in a host-derived lipid membrane, with gp41 and 






After packing of the viral genomes and the necessary viral/host proteins (see 
Table 2), new virions bud from the cell membrane, taking with them a lipid envelope 
derived from the host.  Subsequently, protease cleaves the Gag and Gag-Pol 
polyproteins into the capsid, matrix, nucleocapsid, and p6 proteins (Gag) and RT, 
integrase, and protease enzymes (Pol).  This process is called maturation and results 
in infectious viral particles (Figure 5) (24).  
1.2.3 Reverse Transcription 
 HIV relies on RT for the complex process of reverse transcribing its ssRNA 
genome to dsDNA.  The enzyme is a heterodimer, consisting of a 66 kDa subunit 
containing the enzymatic domains and a catalytically inactive 51 kDa subunit that 
acts as a facilitator for catalysis (25).  Both are encoded by the same gene, but HIV 
protease converts a subset of p66 enzymes to the smaller p51 subunit.  The enzyme 
has a right-handed structure, containing five regions:  a connection domain (the major 
point of contact between the two subunits) and thumb, fingers, and palm domains that 
encircle the catalytic cleft in p66, which also contains an Ribonuclease H (RNase H) 
domain whose sequence is absent in the p51.  Despite the subunits sharing the same 
amino acid sequence (excepting the p51 truncation) their structures and activities are 
vastly different.  p66 is an open and flexible enzyme, capable of synthesizing ssDNA 
from ssRNA and dsDNA from ssDNA, as well as degrading RNA in RNA:DNA 
hybrids via the RNase H domain.  In contrast, p51 is catalytically inactive and 





Figure 6. A crystal structure of HIV RT bound to dsDNA. The p66 fragment is 
represented by dark blue, p51 is light blue, and dsDNA is red.  The domains of the 
enzyme are highlighted in color: palm (purple), thumb (green), fingers (orange), 
connection (yellow), and RNase H (gray).  All of the catalytic functions of the 







 The catalytic cleft in HIV RT is structurally similar to other DNA 
polymerases, particularly to Family A DNA polymerases like the Klenow fragment of 
E. coli pol I (discussed in chapter 3).  Like these pols, it contains aspartic acid 
residues (Asp-110, Asp-185, and Asp-186) that coordinate the two divalent cations, 
which are required for nucleotide incorporation (reviewed in (28)).  These cations act 
as stabilizers during the nucleophilic attack of the incoming dNTP by the 3′ OH of the 
primer.  This role is most likely filled in vivo by the most readily abundant cation, 
magnesium (Mg2+), which exists at an estimated free concentration of ~0.25 mM in 
the cytosol of lymphocytes (29, 30).  The RNase H domain also coordinates divalent 
cations for RNA cleavage, although there is conflicting evidence for both one- and 
two-metal-ion binding sites (reviewed in (31)).  These cations are coordinated by a 
catalytic triad (Asp-443, Asp-498, and Glu-478) in the active site (32). 
 As RT lacks proofreading activity, it is highly error-prone compared to DNA 
polymerases with exonuclease domains.  On average, it makes approximately 3.4 x 
10-5 mutations per bp per cycle in vivo, which is roughly one mutation per replication 
cycle (this does not include mutations generated by host DNA and RNA pols) (33).  
In contrast, replicative polymerases like E. coli pol I have error rates between 10-6 and 
10-8 (34).  This low fidelity results in enormous genetic diversity and is partially 
responsible for HIV’s ability to rapidly evolve resistance to ARVs.    
 The process of reverse transcription (Figure 7) is complex and is primed by 
the tRNAlys that is packaged into the virion, which hybridizes to the PBS on the 5′ 




end of the RNA template, after which RNase H degradation allows dissociation of the 
newly formed DNA.  As the 5′ and 3′ R regions are homologous, the DNA can 
hybridize with the 3′ R in a strand transfer event, which allows full minus-strand 
DNA completion.  Meanwhile, RNase H cleaves the RNA template, leaving behind a 
small polypurine tract (PPT) located roughly 300 nt from the 3′ end of the genome.  
From this, plus-strand DNA synthesis is initiated and the 3′ U5-R-U3 LTR is 
completed.  A second strand transfer event to the 5′ DNA PBS sequence allows 
completion of synthesis and results in a double stranded DNA copy of the genome 
(24).  Because two copies of the RNA genome are packaged into each virion, each 
strand transfer event represents an opportunity for template switching between the 
two RNAs, called recombination.  In addition to the two obligate strand transfers, 
secondary structures that slow synthesis by RT present opportunities for the nascent 
minus-strand DNA to switch to the second RNA genome and continue synthesis 
there.  This switching during synthesis of the minus strand occurs on average 3-10 
times during normal reverse transcription in a T-cell and even more in macrophages.  
This creates chimeric viruses that are composites of two parental sequences and, 
much like sexual recombination in cellular organisms, allows combinations of 
sequences between lineages (reviewed in (35)). 
 Due to its crucial role in viral replication, HIV RT has long been an area of 
study and many questions remain about the function of this fundamental enzyme.  In 
this thesis, I will address the ability of divalent cations to profoundly alter the 
behavior of HIV RT during reverse transcription, as well as present research 




also investigate the ability of Family A DNA polymerases to preferentially bind 







Figure 7.  Reverse transcription of the HIV genome. HIV uses RT to convert the 







Chapter 2: Mechanism of HIV reverse transcriptase inhibition 
by zinc: formation of a highly stable enzyme-primer-template 
complex with profoundly diminished catalytic activity 
 
2.1 Introduction 
HIV RT, like other RTs, possesses both nucleotide polymerization and RNase 
H capabilities.  Both activities require a divalent cation as an integral co-factor in the 
mechanism of catalysis (36, 37).  Under physiological conditions Mg2+ presumably 
functions as the co-factor, however other divalent cations (including Mn2+, Ni2+, and 
Cu2+) can also be used for nucleotide catalysis (38).  Some divalent cations, such as 
Pd+2, Ca2+, Mn2+, and Zn2+, have been shown to inhibit Mg2+-dependent RT activity 
(38, 39, 40, 41, 42).  
 Magnesium binds to RT in the polymerase and RNase H domains where 
binding is coordinated by the acidic catalytic residues within the active sites.  By 
analogy to other DNA polymerases, two Mg2+ ions participate in polymerization via a 
universal "two metal ion" mechanism (reviewed in (28)).  The number of Mg2+ ions 
bound at the RNase H active site is more controversial, as both one and two metal 
mechanisms have been proposed (reviewed in (31)).  In addition to the cation binding 
sites, other sites may also exist on the enzyme.  For example, some reports suggest 
that as many as 21 Mg2+ ions are bound to a single Escherichia coli DNA polymerase 
I molecule (43).  The role, if any, of these additional cations is unclear.   
Many enzymes require cation co-factors that play an intricate role in the 
mechanism of catalysis.  In humans these typically include magnesium, calcium, iron, 




though required to stimulate the activity of several enzymes, typically acts as an 
allosteric regulator involved in cell signaling rather than a co-factor in catalysis.  
Most enzymes that carry out catalysis on nucleic acids have evolved to use Mg2+ as a 
primary cofactor.  Although the majority of the ~10 mM Mg2+ in cells is complexed 
with cellular components, the intracellular concentration of free available Mg2+, 
typically reported to be between 0.25 mM and 2 mM, is still much greater than other 
divalent cations (44, 45, 46, 30, 47).  Unlike Mg2+, other cation co-factors are 
maintained at much lower levels in cells.  The availability of these cations is carefully 
controlled by a combination of ion transporters, binding proteins that sequester the 
cations, and sequestration by cellular nucleotides and within specific cell organelles.  
For example, the concentration of free Zn2+ in cells is in the low nM range despite a 
total concentration (free and bound) of ~0.1-0.5 mM and a plasma concentration of 
~15 µM (45, 48, 49, 50, 51).  The tight regulation is required due to the ability of 
some cations to alter transcription and inhibit or alter the activity of several enzymes.  
Zinc is particularly notable because it is important to many processes in cells and is a 
component of several proteins, particularly zinc finger containing proteins (48, 51, 
52).  In addition, Zn2+ has recently been shown to modulate signal transduction, and 
like Ca2+, serve a cellular second messenger role for specific processes (53, 54).  Zinc 
is also a potent inhibitor of many enzymes, including several viral polymerases (40, 
41, 55-56).  The mechanism of inhibition may take different forms including direct 
displacement of Mg2+ due to higher affinity of Zn2+ for the cation binding site, 




complex mechanisms that involve interactions with substrate or other cofactors 
(nucleotides or nucleic acids for example).   
         This chapter investigates the interaction of HIV-RT with Zn2+ (as well as 
Mn2+ and Ca2+) to determine how it affects RT activity.  The results showed that Zn2+ 
supported both polymerase and RNase H activity at concentrations much lower than 
Mg2+ and was a potent inhibitor of RT in the presence of Mg2+.  Surprisingly, the RT-
Zn2+-primer-template complex was much more stable than the same complex formed 
with Mg2+ while rate of nucleotide incorporation was much slower.  Overall Zn2+ 
inhibits RT by forming what is essentially a “dead-end complex” that can remain 
bound to the primer-template for hours but has very slow incorporation kinetics.  The 
possibility of using Zn2+ or other cations as inhibitors of virus replication is discussed.  
 
 
2.2 Materials and Methods 
Materials– The following reagent was obtained through the AIDS Research 
and Reference Reagent Program, Division of AIDS, NIAID, NIH: pNL4-3 from Dr. 
Malcolm Martin (57).  PCR primers and primers used to prime templates in reverse 
transcription assays were obtained from Integrated DNA Technologies, Inc.  The 
HIV-RT clone was a gift from Dr. Michael Parniak (University of Pittsburg).  HIV-
RT was purified as described (58).  Aliquots of HIV-RT were stored frozen at -80°C 
and fresh aliquots were used for each experiment.  RNase H minus (E478>Q) RT was 
a gift from Dr. Stuart Le Grice, HIV Drug Resistance Program, National Cancer 
Institute, Frederick, MD.  Taq polymerase, T4 polynucleotide kinase, MuLV-RT, and 




calf intestinal alkaline phosphatase (CIP), AMV-RT, and dNTPs were from Roche 
Diagnostics.  DNase I-RNase-free and RNase H were from United States 
Biochemical Corporation.  RNase inhibitor (RNasin) and the phiX174 HinfI digest 
DNA ladder was from Promega.  Radiolabeled compounds were obtained from 
PerkinElmer.  Sephadex G-25 spin columns were from Harvard Apparatus.  
QIAquick PCR Purification Kits and RNeasy Mini Kits for RNA cleanup were from 
Qiagen.  All other chemicals were from Sigma or Fisher Scientific. 
Generation of RNA transcripts– Extension assays were carried out on a 425 nt 
RNA template derived from a 420 nt section of the HIV-1 gag-pol genome region 
(bases 1924-2343 on pNL43) and 5 additional non-HIV nts at the 5′ end.  PCR 
amplification was performed using forward primer 5′-
GATTTAGGTGACACTATAGTCAAACAGAAAGGCAATTTTAGGAAC-3′and 
reverse primer 5′-TATCATCTGCTCCTGTATCT-3′.  Underlined bases contain an 
SP6 promoter and italicized bases correspond to the 5 non-HIV nts.  After 
amplification (94°C/3 min followed by 25 cycles of: 94°C/1 min, 50°C/1 min, 72°C/1 
min, followed by a final extension at 72°C for 5 min), template DNA was purified 
using the QIAquick PCR Purification Kit and 8 µls was used in RNA transcription 
reactions with SP6 polymerase according to the manufacturer instructions.  Reactions 
were allowed to proceed for 3 hours, at which point they were treated with 0.4 
units/µl of DNase I for 20 minutes at 37°C.  RNA was purified using the RNeasy 
Mini Kit and quantified using UV spectroscopy. The 60 nt RNA for the RNase H 
assays was prepared by digesting 10 µg of pBSM13+ (Stratagene) plasmid with 20 




used in a transcription reaction with T7 RNA polymerase as described above.  
Transcription reactions were extracted with phenol:chloroform:isoamyl alcohol 
(25:24:1) and precipitated with ethanol. The RNA was gel purified on an 8% 
denaturing polyacrylamide gel, located by ultra violet shadowing, and recovered by 
the crush and soak gel elution method (59).  The amount of recovered RNA was 
determined spectrophotometrically from optical density.  Gel-purified RNAs were 
dephosphorylated with CIP using the manufacturer’s protocol and supplied buffer.  
The reactions were extracted and precipitated and the recovered RNA was end-
labeled using T4 polynucleotide kinase as described below.  The material was then 
run on a second denaturing polyacrylamide gel, located by autoradiography and 
recovered as described above.  This material was hybridized to a DNA 
oligonucleotide as described below.  The sequence of the recovered RNA was: 5′-
GGGCGAAUUCGAGCUCGGUACCCGGGGAUCCUCUAGAGUCGACCUGCA
GGCAUGCAAGCU-3′.   
5′ end-labeling of DNA primers for reverse transcription and off-rate 
determinations, and RNA template for RNase H assays– The reverse DNA primer 
(see above), DNA primer for the binding half-life determination assays (33 nt: 5′-
TCCCCGGGTACCGAGCTCGAATTCGCCCTATAG-3′), and the RNA template 
for the RNase H assays (see above) were 5′ end-labeled using T4 polynucleotide 
kinase and γ−32P-ATP using the manufactures protocol and supplied buffer.  The 
material was run through a G-25 sephedex column to remove excess ATP.  
Nucleic acid hybridization– Hybrids were prepared by mixing RNA (425 nt 




reverse transcription assays at an approximately 1:1.5 ratio (template:primer) of 3′ 
termini in buffer containing 50 mM Tris-HCl (pH=8), 80 mM KCl and 1 mM DTT.  
For binding half-life determination assays the end-labeled 33 nt primer described 
above was hybridized to a 50 nt DNA (5′-
TTGTAATACGACTCACTATAGGGCGAATTCGAGCTCGGTACCCGGGGATC-
3′) and for RNase H assays, the end-labeled 60 nt RNA was hybridized to a 23 nt 
DNA (5′-AGGATCCCCGGGTACCGAGCTCG-3′), each at a 1:1 ratio.  For all 
hybrids, the mixtures were heated to 65°C for 5 min, and then cooled slowly to room 
temperature. 
Reverse transcriptase primer extension assay– Hybridized primer-template 
was incubated in 21 µl of buffer containing 50 mM Tris-HCl (pH=8.0), 80 mM KCl, 
1 mM DTT, 100 µM each dNTP (final concentration, unless otherwise noted), 0.2 
units/µl RNase inhibitor, and varying concentrations of ZnCl2, MnCl2, CaCl2, or 
MgCl2 (as indicated in legends).  Following a 3 minute pre-incubation at 37°C, 4 µls 
of RT (final concentration of 25 nM) was added to begin extension.  The final 
template concentration was 5 nM in the 25 µl reactions.  The reactions were stopped 
by addition of 2X loading buffer (90% formamide, 10 mM EDTA (pH=8.0), and 
0.025% bromophenol blue and xylene cyanol) at the indicated times.  Samples were 
separated on 6 or 8 % denaturing urea gels (7M urea, 19:1 acrylamide:bisacrylamide), 
dried, and imaged using a Fujifilm FLA-5100 or FLA-7000. 
RNase H assays– Hybridized RNA-DNA from above (25 nM final 
concentration) was incubated in 21 µl of buffer containing 50 mM Tris-HCl 




concentrations of MgCl2 or ZnCl2 (as indicated in legend to Figure 12).  A 3 min 
preincubation at 37°C was followed by addition of 4 µls of HIV-RT (10 nM final 
concentration) and incubation was continued for 5 min (unless otherwise indicated).  
Products were resolved on 10% denaturing gels as described below. 
Assays to determine RT-substrate binding half-lives– Half-life determination 
assays for reactions with RT and ZnCl2, MnCl2, or MgCl2 were performed as 
described previously (34).  Time points are indicated in the Fig. 7.  
Processivity assay– Processivity assays were conducted using the conditions 
stated above under Reverse transcriptase primer extension assay with the following 
modifications: (1) the volume of the preincubation reaction was 50 µls; (2) divalent 
cations and dNTPs were not included in the preincubation step; (3) RT (50 nM final 
concentration) was included in the preincubation step; (4) reactions were initiated by 
the addition of a 10 µl solution containing a divalent cation (final concentration 400 
µM or 2 mM for ZnCl2 and MgCl2, resp.); dNTPs (final concentration 100 µM each) 
and poly(rA)-oligo(dT) (final concentration 0.4 µg/ul) in 50 mM Tris-HCl (pH=8), 80 
mM KCl, 1 mM DTT.  Five µl aliquots were removed at the indicated times (Figure 
13) and reactions were terminated with 5 µl of 2X loading buffer (see above).  
Samples were run on a 6% denaturing gel as stated above.  The addition of poly(rA)-
oligo(dT) limits synthesis to preformed complexes of RT-primer-template and further 
limits synthesis to a single processive cycle (35).  Poly(rA)-oligo(dT)  used in the 
reactions was prepared by mixing oligo (dT20) with poly(rA) at a 1:8 ratio (w/w) in 10 
mM Tris-HCl (pH 7.5).  The mixture was incubated for 10 minutes at 37°C and slow 




Determination of average extension rate– Average extension rates for 
reactions with 400 µM ZnCl2 or 2 mM MgCl2 were determined using results from the 
reverse transcription primer extension assays and the Fuji MultiGauge software 
(version 3.0) on the FLA-5100 or FLA-7000 and the molecular weight determination 
program.  Thirty and one min reaction times were used for ZnCl2 and MgCl2 
reactions, respectively.  At these time points, products had not reached the end of the 
template.  The average extension rate was estimated by calculating the size in nts of 
each band on the gel (s) and subtracting the primer length (20 nt), then using the 
imager to determine the relative proportion (with the total being set to 1) of the total 
extended primers to which each band corresponded (y).  The band’s contribution to 
the average extension rate can be represented by the following equation: (s-20)*y.  
The average extension rate can then be calculated using the following expression, 





As an example, if a 60 second reaction produced 4 extension product bands of sizes 
30, 40, 60, and 80 nts that were of equal intensity then the average extension rate 
would be [(30-20)*0.25+(40-20)*0.25+(60-20)*0.25+(80-20)*0.25]/60 which equals 
32.5 nt/sec.  
Gel electrophoresis– Denaturing polyacrylamide gels (19:1 acrylamide:bis-








2.3.1 Zn2+ potently inhibits HIV-RT catalysis in the presence of Mg2+ 
Although Zn2+ has been shown to inhibit HIV-RT activity, the mechanism and 
nature of the inhibition have not been investigated.  To investigate this, primer-
directed reverse transcription was performed using a 425 nt RNA template derived 
from the gag-pol region of the HIV genome primed with a 20 nt 5′ 32P end-labeled 
DNA primer (Figure 8A).  Full extension of the primer to the end of the template 
produced a 425 nt DNA product (as indicated in Figure 8B).  In these experiments 
reactions were performed using 100 µM of each dNTP.  Control reactions performed 
in the absence of Mg2+ with ZnCl2 (lanes 2 and 3, 1 and 30 min, resp.) and ZnSO4 
(lanes 4 and 5, 1 and 30 min, resp.) at 400 µM each showed synthesis with Zn2+ under 
optimal conditions (see Figure 10).  Both ZnCl2 and ZnSO4 gave comparable results 
and the former was used for all other experiments.  Other reactions were performed 
for 1 or 30 min (as indicated) with 2 mM MgCl2 (optimal for extension rate (see 
Figure 11) in the absence (Ø) or in the presence of increasing amounts of ZnCl2.  
Even very small amounts of Zn2+ (0.5-2 µM, first 3 lanes following the Zn2+ free 
reaction) had a detectable effect on the rate of nucleotide addition (based on results 
with 1 min reactions) to the primer and a more dramatic affect was observed at 5 µM, 
even thought the ratio of Mg2+:Zn2+ was 400:1 at this concentration.  Severe 
inhibition was observed between 25 and 800 µM Zn2+.  Both the maximum length of 




with the former decreasing and the latter increasing.  Reactions performed for 30 min 
indicated that the inhibition caused by low amounts of Zn2+ (0.5-25 µM) did not 
prevent the production of fully extended products although the quantity of those 
products was reduced at the expense of more intense pausing.  The profile of 
synthesis in the presence of 2 mM Mg2+ plus 400 µM Zn2+ compared to 400 µM Zn2+ 
alone (lanes 3 and 5) were similar, suggesting that these reactions were being driven 





Figure 8:  Reverse transcription with 2 mM Mg2+ and increasing Zn2+ 
concentrations.  (A) Schematic representation of the primer-template used for 
assays.  Numbers indicate size in nts. (B)  Primers labeled at 5′ end were hybridized 
to the RNA template and reactions were performed in the presence of 2 mM MgCl2 
and increasing concentrations of ZnCl2.  Reactions were stopped after 1 min or 30 




ZnCl2 in reactions was 0.5, 1, 2, 5, 25, 100, 400, 800 µM.  Lane M, size marker in nts 
as indicated; lane 1, no enzyme; lane 2 and 3, 400 µM ZnCl2 with no MgCl2 for 1 and 
30 min, resp.; lane 4 and 5, 400 µM ZnSO4 with no MgCl2 for 1 and 30 min, resp.; 
lane Ø, 2 mM MgCl2 with no ZnCl2.  Positions of the 20 nt primer and full extension 





2.3.2 Zn2+ is a more potent inhibitor of HIV-RT than Ca2+ and Mn2 
Both Ca2+ and Mn2+ have also been shown to inhibit HIV-RT (see 
Introduction).  These physiologically relevant divalent cations were compared to Zn2+ 
in an inhibition assay in the presence of 2 mM Mg2+ as described above but in 2 min 
reactions (Figure 9).  The Zn2+, Ca2+, and Mn2+ were at 0, 7.8, 31, 125, 500, or 2000 
µM.  All three cations inhibited extension but Zn2+ was much more potent than the 
other two.  The length of the longest extended products had decreased by ~50% in the 
presence of just 7.8 µM Zn2+ while ~500 µM Ca2+ or Mn2+ was required to observe 
the same inhibition.  In general, inhibition of extension was accompanied by an 
increase in pausing rather than a decrease in the amount of total primers that were 
extended.  At the higher concentrations some decrease in total primer extension was 






Figure 9: Inhibition of reverse transcription with 2 mM Mg2+ by increasing 
concentrations of Zn2+, Ca2+ and Mn2+.  Reactions were performed on the primer-
template shown in Figure 8A for 2 min with 2 mM MgCl2 and increasing 
concentrations of the indicated divalent cation (all chloride salts) as follows: 7.8, 31, 
125, 500, and 2000 µM.  Lanes and markings are as indicated in Fig. 1B with the 







Figure 10: Reverse transcription with Zn2+ alone and various dNTP 
concentrations.  Reactions were performed on the primer-template shown in Figure 
8A for 30 min with increasing concentrations of ZnCl2 as follows: 5, 10, 25, 100, 200, 
400, 800, 1500, and 3000 µM.  The concentration of each of the 4 equimolar dNTPs 
in the reactions is noted above the lanes.  Lane M, refer to Figure 8B; lane 1, 30 min 
reaction with 2 mM MgCl2 and 100 µM dNTPs; lane 2, reaction with no enzyme.  




2.3.3 Zn2+ supports the RNase H activity of HIV-RT at concentrations 
similar to those observed for nucleotide extension 
Reactions performed in the absence of Mg2+ showed that Zn2+ supports RT 
synthesis at a highly reduced incorporation rate (Figure 10).  Even at 5 µM in these 
30 min reactions some extension of the primer was observed at all dNTP 
concentrations, indicating that Zn2+ binds with high affinity to RT.  The maximum 
rate of nucleotide incorporation was observed at 400 µM Zn2+ when 100 µM 
equimolar dNTPs (400 µM total) were used.  An assay performed with a homologous 
DNA template yielded the same optimal concentration and similar profile with 
respect to extension rate vs. the concentration of Zn2+ (data not shown).  Since 
nucleotides can chelate divalent cations (36) and Zn2+ catalyzed synthesis peaks at a 
low concentration, the optimal determined with higher dNTP concentration is 
unlikely to reflect the actual affinity of Zn2+ for RT, as most Zn2+ would be 
complexed with nucleotides under these conditions.  Reactions performed with 10 or 
1 µM dNTP concentrations were optimal at ~100 and ~25 µM Zn2+, respectively.  
There was a decline in extension length with lower dNTP concentrations indicating 
that the Zn2+ catalyzed reactions require high nucleotide concentrations to proceed at 
a maximal rate.  Overall the results with the lowest dNTP concentration (1 µM) 
where very little Zn2+ is sequestered indicated that HIV-RT has a very high affinity 
for Zn2+.  For comparison purposes, a titration with Mg2+ and Mn2+ (Ca2+ showed no 
catalytic activity at any concentrations tested (data not shown)) at 100 µM dNTPs 
was conducted (3 min reactions in each case) (Figure 11).  Like Zn2+, Mn2+ showed 




RT as most of the free Mn2+ would have been otherwise chelated under these 
conditions.  This is consistent with previous results indicating that there is at least one 
high affinity binding site for Mn2+ on RT (39).  In contrast, Mg2+ demonstrated a 
broad activity peak with an optimal at 2 mM.  Some synthesis with Mn2+ was 
observed all the way down to 3.9 µM while synthesis with Mg2+ was first observed at 
31 µM.  At 2 mM Mg2+ and 400 µM total dNTPs the free concentration of Mg2+ in 
the reactions would be about ~1.6 mM (60) indicating a much higher concentration 
optimum than Zn2+ or Mn2+.  These results are consistent with Zn2+ showing strong 
inhibition of reactions with Mg2+ even when present at concentrations that were ~100-
fold lower than Mg2+ (Figure 8 and Figure 9).  Inhibition by Mn2+ appeared less 
potent even though it apparently binds RT as tightly as Zn2+, probably due to the 
much more efficient synthesis of HIV-RT in the presence of Mn2+ compared to Zn2+.  
For example, the maximum extension rate for reactions performed under optimal 
conditions (100 µM dNTPs with 2 mM, 400 µM, and 250 µM divalent cation, for 
Mg2+, Zn2+, and Mn2+, respectively) was determined by calculating the lengths of the 
longest products in reactions that had not proceeded to the end of the template, and 
dividing by the reaction time in seconds.  Values of 3.5, 1, and 0.1 nt/sec were 
determined for Mg2+, Mn2+, and Zn2+ respectively.          
An additional control was also performed in these assays and is shown in lane 
2 of Figure 11 and lane 2 of Figure 12B.  In these assays RT was incubated with the 
substrate but divalent cation was omitted from the reactions.  Depending on the 
purification procedures, small amounts of divalent cation can co-purify with enzymes.  




additional divalent cation.  No activity was observed when divalent cation was 
omitted from the reactions indicating that both polymerase (Figure 11) and RNase H 







Figure 11: Reverse transcription with various concentrations of Mg2+ and Mn2+.  
Reactions were performed on the primer-template shown in Fig. 1A for 3 min with 
100 µM each dNTP and increasing concentrations of MgCl2 or MnCl2 as follows: 3.9, 
7.8, 15.6, 31.3, 62.5, 125, 250, and 500 µM, followed by 1, 2, 4, 8, and 16 mM.  Lane 
M, refer to Fig. 1B; lane 1, no enzyme; lane 2, enzyme without additional divalent 
cation.  Lanes where optimal synthesis occurred are denoted on the figure with an 





Figure 12: RNase H digestion with HIV-RT in the presence of varying 
concentrations of Zn2+.  (A) Schematic diagram of the primer-template.  A 5′-
labeled 60 nt RNA is hybridized to a 23 nt DNA primer.  (B)  In order, control lanes 
refer to: 1) no enzyme, 2) enzyme without additional divalent cation, and 3) E. coli 
RNase H digestion of substrate.  Lanes labeled 4 and 5 contain 2 mM MgCl2 and no 




concentrations were 2, 5, 10, 25, 100, 200, 400, 800, and 1200 µM.  The 
concentration for optimal RNase H activity is noted with an arrow.  Positions of uncut 





2.3.4 HIV-RT forms a very stable catalytically competent complex with 
primer-template in the presence of Zn2+ that traverses the template slowly but 
can remain associated for hours 
Since the extension rate of RT was ~35 times greater in the presence of Mg2+ 
compared to Zn2+ (see above), it was reasonable to assume that processivity (average 
numbers of nucleotides added to the primer in a single binding event between RT and 
the substrate) would be much greater with Mg2+.  Surprisingly, this was not the case.  
Reactions to test processivity were performed on the primer-template shown in Fig. 
1A by pre-binding RT to the preformed primer-template then adding dNTPs and 
divalent cation along with an excess of poly(rA)-oligo(dT) to sequester enzymes that 
were not bound to or had dissociated from the primer-template.  This limits synthesis 
to a single binding even between the enzyme and substrate (61).  Reactions with 2 
mM Mg2+ (left panel, Figure 13) showed the expected profile.  Primers were extended 
at a maximum rate of ~3.5 nt/sec with some extension products reaching the end of 
the 425 nt template by 2 min and more by 4 min.  The extension profile of reactions 
performed for 8 and 16 min looked very similar to those performed for 4 min 
indicating that the single round of enzyme extension was essentially complete in 4 
min.  In contrast, the first time point shown for the reactions with 400 µM Zn2+ was 
15 min.  In this case reactions proceeded at the expected ~0.1 nt/sec and some 
products reached the end of the template by about 1 hr.  Fully extended products 
continued to accumulate even up to the final 4 hour time point, although there was 
just a small increase between 3 and 4 hours and those profiles looked very similar.  It 




template for hours.  Although the maximum rate of synthesis was ~0.1 nt/sec, on 
average polymerases moved much more slowly, at a calculated rate of 0.022 ± 0.003 
nt/sec for Zn2+ as compared to 1.7 ± 0.4 nt/sec for Mg2+ reactions (results are an 
average ± S.D. from 3 or more reactions using 30 min and 1 min time points for 400 
µM Zn2+ and 2 mM Mg2+, respectively; see Methods for calculation).  Despite this, 
the final processivity on this template was only modestly higher for Mg2+. 
To test the stability of the enzyme-substrate complexes further, the half-life 
(t½) of RT for binding to a DNA-DNA primer-template was determined in the 
presence of Zn2+, Mn2+ and Mg2+ (Figure 14).  This experiment required the use of 
DNA-DNA since off-rates in the presence of divalent cation cannot be easily 
measured with RNA-DNA except with RNase H mutant enzymes.  Remarkably, 
complexes with Zn2+ and Mn2+ were ~130 (t½=220±60 min) and ~45 (t½=77±1 min) 
times more stable than those with Mg2+ (t½=1.7±1.0 min).  This is consistent with the 
ability of single enzyme molecules to remain bound to the template for such a long 
time in the processivity experiments (Figure 13).  It is important to note that the 
dramatic differences in t½ observed with DNA-DNA only provide a qualitative 
comparison between affinity differences that may occur during DNA synthesis on an 
RNA template or even a DNA template (see Discussion).  Still the results clearly 
suggest that Zn2+ and Mn2+ lead to more stable RT-primer-template complexes in 





Figure 13: HIV-RT processivity with Mg2+ and Zn2+.  Extension with 2 mM 
MgCl2 or 400 µM ZnCl2 was performed with the primer-template in Fig. 1A and in 
the presence of a non-radiolabeled poly(rA)-oligo(dT) trap which limits primer 
extension to a single binding event between RT and the primer-template.  Lane 1, no 
enzyme; lane 2, trap control: enzyme was mixed with the trap then incubated with 
primer-template in standard reaction conditions for 16 min or 4 hr for Mg2+ and Zn2+ 
reactions, resp.;  lane 3, primer extension in the absence of trap for 16 min or 4 hours 
for Mg2+ and Zn2+ reactions, respectively.  Time points for trap reactions with MgCl2 
were 30s, 1, 2, 4, 8, and 16 min, and for ZnCl2, 15 and 30 min, followed by 1, 2, 3, 









Figure 14: Plot of RT-primer-template complex binding stability in the presence 
of Mg2+, Mn2+, and Zn2+.  Half-lives are indicated with their respective curve.  
Results are and average of 3 exp. ± standard deviations.  Experiments were performed 






2.3.5 Other viral RTs from AMV and MuLV as well as an RNase H 
minus HIV mutant (HIV-RTE478>Q) can also use Zn2+ for nucleotide 
incorporation 
Nucleotide incorporation was also tested with 3 other RTs including an RNase 
H minus form of HIV-RT (HIV-RTE478>Q) and two other viral RTs, AMV-, and 
MuLV-RT (Figure 15).  Not only did all 3 RTs show activity, but peak activity 
occurred at ~400 µM Zn2+ in all cases (assay were with 400 µM total dNTPs).  The 
similar results likely derive from common active site architecture in these closely 





Figure 15: Reverse transcription with various RTs in the presence of Zn2+.  
Extension was performed with the primer-template from Figure 8A with the indicated 
enzyme.  Reactions were for 30 min and ZnCl2 concentrations were as follows: 100, 
200, 400, and 800 µM, followed by 1.5 and 3 mM.  Lane M is as in Figure 8B.  
Optimal concentrations for extension are noted for each enzyme with an arrow.  Lane 
–E, no enzyme control; lane 1, extension with the indicated enzyme for 30 min with 2 






As with Ca2+ and Mn2+, previous reports have also shown that Zn2+ inhibits 
HIV-RT nucleotide incorporation in the presence of Mg2+ (see 2.1 Introduction).  The 
mechanism of inhibition has been best studied using Mn2+.  Bolton and colleagues 
(39) have proposed that Mn2+ inhibits TY1 and HIV-RT by binding with high affinity 
and displacing Mg2+ at one of two proposed divalent cation binding sites near the 
polymerase active site.   The authors propose that the two sites do not equally affect 
catalysis and the site that Mn2+ binds tightly to is dominant.  Therefore, even if Mg2+ 
occupies the second site, RT reverts to a Mn2+ catalysis mode similar to what is 
observed in the presence of Mn2+ alone.   This mode is much less efficient with 
respect to the rate of incorporation.  The model is supported by mutational analysis as 
well as the observance of two divalent cations in the polyrmerase domain of HIV-RT 
in some crystals (62).  Interestingly, TY1 retrotransposon mutants that could 
overcome Mn2+ inhibition mapped not to the polymerase but to the RNase H domain 
(63).  This led the authors to propose a model where mutations in the RNase H 
domain could influence polymerization through allosteric effects.  The fact that 
mutations in the polymerase domain conferring resistance were not found does not 
necessarily mean that this domain is uninvolved in the observed inhibition by Mn2+.  
It is possible that mutations which alter Zn2+ binding may have a severe impact on RT 
activity and are therefore not selected.   
 The model proposed for Mn2+ is consistent with what was observed for Zn2+ in 
the current experiments, although our findings do not necessarily support this model 




one or more binding site in the polymerase domain that control catalysis.  What was 
clear from the current results is that Zn2+ is a more potent inhibitor of Mg2+ catalysis 
than Mn2+ or Ca2+, as it is required at a lower concentration to inhibit extension 
(Figure 9).  This is probably not due to a higher affinity of Zn2+ for RT as the optimal 
concentrations for Zn2+ and Mn2+ catalysis in the absence of Mg2+ were comparable 
(~400 µM and 250 µM for Zn2+ and Mn2+, resp., in the presence of 400 µM total 
dNTPs).  Primer extension in the presence of Mn2+ was, however, much more 
efficient than with Zn2+ (Figure 8 and Figure 11, note time difference in reactions).  
The ability of polymerases to use Mn2+ in place of Mg2+ in vitro has been well 
documented and some polymerases function as well or even better with Mn2+, 
although it tends towards lower polymerase fidelity (28).  Since experiments reported 
here essentially evaluated polymerization efficiency by the rate of extension and the 
length of the products that were produced, the greater inhibition of Mg2+ catalysis by 
Zn2+ probably resulted from Zn2+ producing a more catalytically deficient enzyme.  
In contrast to Zn2+ and Mn2+, no catalysis was observed with Ca2+, while the level of 
inhibition of Mg2+ catalysis was similar to Mn2+.  RT’s inability to use Ca2+ for 
catalysis is not surprising as it is not typically a co-factor in catalysis for enzymes 
(see 2.1 Introduction).  Specific properties of Ca2+, which differ markedly from Mg2+, 
make it a poor candidate for nucleotide catalysis by polymerases (discussed in (64)).  
Ca2+ is also known to inhibit other DNA polymerases (65) and has been used to help 
stabilize crystal structures of some polymerases by preventing catalysis during crystal 
formation.  Some crystals made with Ca2+ show this ion bound at the pol active site 




Sulfolobus solfataricus DNA polymerase, has been reported to be able to use Ca2+ 
for nucleotide polymerization, though less efficiently than Mg2+ (66). 
Since RNase H catalyzed cleavage of the RNA-DNA hybrid was observed in 
the presence of Zn2+ alone, it was clear that this cation can bind to the RNase H 
active site and stimulate cleavage in a manner similar to Mn2+ (63).  Also notable was 
the ~10-25 µM Zn2+ optimal for cleavage (Figure 12), which was very close to the 
optimal concentration of Zn2+ for polymerization in the presence of low (1 µM) 
concentrations of dNTPs (Figure 10).  This suggests that the affinity for Zn2+ at the 
catalytic binding sites in the polymerase and RNase H domains are similar, and that 
Zn2+ binds with greater affinity at these sites than Mg2+ which requires much higher 
concentrations for optimal activity (Figure 11).  Interestingly, all the RTs that were 
tested including HIV, HIVE478>Q, AMV and MuLV showed similar optimal Zn2+ 
concentrations for nucleotide incorporation.  This suggests that the active sites of 
these RTs have similar affinity for Zn2+.   
HIV-RTE478>Q is a commonly used enzyme for studying polymerization 
properties in the absence of RNase H activity.  The glutamic acid to glutamine 
mutation in the RNase H active site abrogates RNase H activity and also disrupts a 
divalent cation binding site in the RNase H domain.  This enzyme has polymerization 
properties that essentially mimic wild type enzyme, although it does have altered 
binding characteristics to primer-template in the absence or at low concentrations of 
Mg2+ (67, 68).  Polymerization with HIV-RTE478>Q occurred in the presence of Zn2+ 
with a concentration optimum and profile that was similar to wild type RT (Figure 




in the wild type enzyme (data not shown).  Overall the results suggest that the 
mutation in the RNase H domain had no effect and an allosteric interaction of the 
type reported for TY1 RT (see above) was not observed.  It is important to note that 
although the E478>Q mutation would presumably alter divalent cation binding in the 
RNase H domain, it is not clear how it would be changed and if the mutation would 
abrogate the binding of one or more cations.  Therefore the results do not rule out 
potential allosteric interactions of the type proposed by others.   
The dramatic increase (>100 fold) in the stability of RT-Zn2+-primer-template 
compared to RT-Mg2+-primer-template complexes was surprising.  Importantly, the 
method for measuring dissociation did not directly reflect dissociation that occurs 
during active DNA synthesis.  No dNTPs were present and the polymerase was not 
cycling thorough the various phases of nucleotide incorporation (primer-template 
binding, nucleotide binding, catalysis and translocation, then dissociation).  Each of 
these phases may have different dissociation rates.  Reports have also shown that 
binding of RT to nucleotides can stabilize binding (69).  Finally, DNA-DNA primer-
templates were used in the off-rate experiments as RNA-DNA cannot be used since it 
is degraded by RNase H activity in the presence of divalent cation.  Experiments have 
shown that in the presence of Mg2+, HIV-RT binds more stably to both RNA-DNA 
and DNA-DNA (67), so the results may under-represent the stability of Mg2+ 
complexes.  Processivity measurements can be used as an indicator of dissociation 
during active synthesis although they cannot be used to directly calculate a 
dissociation rate.  The processivity is dependent on several factors including the 




polymerase dissociation and incorporation rates.  Processivity was greater in the 
presence of Mg2+ than with Zn2+ as the average length of extended products was 
clearly greater with Mg2+, but the difference was relatively small considering that RT 
incorporated nucleotides about 35 times more rapidly in the presence of Mg2+.  This 
large difference in incorporation rate is compensated by very stable binding in the 
presence of Zn2+.  With Zn2+, RT molecules were able to remain bound to the primer-
template for hours even though nucleotides were being added to the primer at a 
maximal rate of ~ 1 every 10 seconds and at an average rate that was much less than 
this (see Results and Figure 14).  This essentially means that polymerases stalled for 
long periods of time after each nucleotide addition but did not dissociate from the 
template.  In contrast, extension with Mg2+ was essentially complete after 4 min as 
paused products remained stable and the level of fully extended primers did not 
change beyond this time point.  Overall the processivity experiment supports the 
results from the off-rate experiments and indicates that the RT-Zn2+-primer-template 
complex is extremely stable.  The reason for this high stability is unclear.  Differing 
effects of the divalent cations on the template structure cannot be ignored as 
contributing factors and also the lower concentration of divalent cation that was used 
in the Zn2+ vs. Mg2+ experiments may have had some effect.  Still, these would not be 
expected to account for the greater than 100-fold difference in off-rates.  
Interestingly, RT-Mn2+-primer-template complexes were also more stable than those 
formed with Mg2+, though to a lesser extent (Figure 14).  Likewise, Mn2+ also 
reduced the rate of nucleotide incorporation, again to a lesser extent than Zn2+.  This 




of RT that is conducive to tight binding but not fast incorporation kinetics, or that 
they stabilize a tight binding confirmation and slower catalysis occurs because of 
relatively poor chemistry compared to Mg2+ (28).   For example, they could promote 
the “productive” vs.  “nonproductive” RT conformation postulated by Whörl et al. 
(70), the former of which is proposed to be more stable. 
In conclusion, Zn2+ inhibits HIV-RT synthesis not by directly stopping 
catalysis, but by forming a highly stable complex that has very slow incorporation 
kinetics.  The RT-Zn2+-primer-template complex can be thought of as a “dead-end 
complex” since it ties up RT- potentially for hours - in a complex that is from a 
kinetic perspective, minimally productive.  HIV-RT apparently has higher affinity for 
Zn2+ (and Mn2+ and Ca2+ also) than Mg2+ at one or more of the divalent cation 
binding sites.  Therefore, relatively low concentrations of Zn2+ can inhibit RT 
extension in the presence of much higher concentrations of Mg2+.  Since Zn2+ has 
relatively low toxicity (71) and can inhibit RT extension at low concentrations (just a 
few µM was required to slow extension in the presence of 2 mM Mg2+, Figure 8), it 
could, at least in theory, be useful for slowing viral replication and zinc-based 
compounds present an opportunity to exploit a weakness in HIV that might present a 
novel avenue for future drug development.  However the possibly of using 
supplements or natural minerals including Zn2+ must be approached with caution.  
Even though Zn2+ can inhibit RT at low-µM concentrations that are lower than the 
level of total Zn2+ in cells and plasma, they are still ~2-3 orders of magnitude greater 
than the level of free available Zn2+ in cells (see 2.1 Introduction).  In addition, 




bloodstream unless there was a specific delivery mechanism.  Finally, µM 
concentrations of free Zn2+ in cells would almost certainly have profound effects on 
the transcription of specific genes, the oxidation state of cells, and general heath (see 
2.1 Introduction and (71)).  Despite these hurdles, the work described in this report 
could help set the stage for further investigations with other cations or cation 










3.1.1 SELEX and Aptamers 
Single-stranded nucleic acids, like amino acid chains in proteins, have the 
ability to fold into secondary and tertiary structures based on their sequence.  In vivo, 
this is crucial for the function of biologically active RNAs, such as ribosomes and 
tRNAs, but this trait has been exploited to design artificial oligonucleotide and 
peptide ligands that possess shapes necessary for targeted binding to other molecules.  
These are called aptamers, from the Latin word apto meaning ‘to fit’.   
Manually designing aptamers is difficult, but in 1990 the Gold and Szostak 
labs independently developed a technique to repeatedly enrich pools of nucleic acids 
for sequences that bound tightly to a target molecule, providing a robust method for 
aptamer generation.  The Szostak lab called this in vitro selection and isolated ssRNA 
aptamers with tertiary structures that were able to bind selectively to organic dyes 
(72).  The Gold lab’s similar process, Systematic Evolution of Ligands by 
Exponential Enrichment (SELEX), was used to isolate ssRNAs that bound the T4 
DNA polymerase (73).   
SELEX relies on the concept that some sequences will naturally fold into 
secondary or tertiary structures that are able to bind targeted molecules.  By creating a 




possible that some members of the pool will be able to bind to the target in a complex 
that allows separation from those that cannot bind; common separation techniques are 
gel shift, capillary electrophoresis, nitrocellulose binding, or column chromatography, 
among others.  These selected sequences can then be amplified to create a second 
enriched pool that only contains target-binding sequences.  This process is repeated 
six to twelve times, resulting in an enriched pool of aptamers that bind with high 
affinity and specificity to the molecule of interest (often these aptamer:target 
complexes have a dissociation constant, Kd, in the low-nM range).  
A general aptamer discovery SELEX protocol begins with a large initial pool 
of ssRNA, which all contain a random region (usually 20-80 nt) flanked by known 
fixed sequences (one of which carries an RNA polymerase promoter, usually T7 
RNA polymerase).  After selection with the target molecule, the ssRNA is amplified 
by RT-PCR into a DNA pool, using the fixed regions as primer binding sites.  These 
sequences are then transcribed into ssRNA from the promoter, generating a pool with 
higher affinity for the target.  The process is repeated until the pool’s binding affinity 
no longer increases with subsequent rounds of selection (a variation on this is shown 
in Figure 19). 
There are several versions of this protocol, each with advantages and 
disadvantages:   
• Substrates 
o ssRNA SELEX requires an RT step and produces aptamers that 
are less stable than their DNA counterparts.  This can be 




and protect the aptamer from nuclease digestion, but that 
increases the cost of the aptamer and may affect binding 
affinity to the target.    
o ssDNA SELEX, which eliminates the RT step  but requires the 
generation of ssDNA, which is more difficult than producing 
ssRNA.  An advantage of DNA aptamers is their inherent 
stability compared to RNA. 
o Xenonucleic acid (XNA) SELEX, which uses synthetic nucleic 
acid alternatives to RNA or DNA.  XNAs contain 
modifications of the naturally occurring deoxyribose (DNA) or 
ribose (RNA) sugar backbone, which can enhance stability (as 
in the case of the RNA analog locked nucleic acid, LNA, 
which has a methylene bridge connecting the 2´ oxygen atom 
to the 4´ carbon, preventing hydrolysis) or reduce recognition 
of the enzyme by nucleases (as seen with anhydrohexitol 
nucleic acid, HNA).  XNA SELEX relies on modified enzymes 
that can transcribe between XNA and DNA.  XNAs are 
attractive alternatives to DNA/RNA because they are able to 
avoid detection or destruction by most nucleic acid-recognizing 
enzymes (74).  Unfortunately, SELEX with XNA is 
cumbersome and is limited by cost and availability of the 






o Minimal primer SELEX uses shorter fixed sequences to 
reduce the impact that these regions might have on the 
selection outcome. 
o Primer-free SELEX eliminates the fixed sequences entirely 
during the selection process, but requires a ligation step to 
reintroduce fixed regions to allow for PCR.   
o Primer-template SELEX, a process developed in the 
DeStefano lab, uses restriction enzymes to create pools of 
dsDNA with a single recessed 3′ terminus, mimicking the 
natural substrate primer-template of DNA polymerases 
(described more fully in Figure 19).   
Using these techniques, aptamers against several different targets have been 
produced: the HIV TAR (75), RT (76), and Env (77), CD4 (78), thrombin (79), 
prostate specific antigen (PSA) (80), and many others.  Due to their sensitivity and 
specificity, aptamers can perform the same functions as antibodies and are both easier 
and cheaper to produce.  DNA aptamers, in particular, have a longer shelf life than 
antibodies (RNA aptamers, while inherently less stable, can be protected by chemical 
modification to increase their resistance to hydrolytic cleavage).  Another strength is 
their potential for reuse:  as nucleic acids can be heated to denature their structure, 
aptamers can be dissociated from the targets and then cooled to regain their active 
conformation.  Due to these benefits, aptamers have been incorporated into biomarker 




Currently, only a single aptamer-based treatment has been approved for use by the 
FDA: Macugen, an aptamer targeting the vascular endothelial growth factor (VEGF), 
which is used to treat age-related macular degeneration (82).  Other therapeutics are 






Name Type Target Condition Phase Company 
Pegaptanib 





AS1411 DNA Nucleolin Acute Myeloid Leukemia Phase II 
Antisoma 
Research 
REG1 RNA Coagulation Factor IX 
Coronary Artery 
Disease Phase II 
Regado 
Biosciences 
NOX-E36 RNA CCL2 Type 2 Diabetes Mellitus Phase I 
NOXXON 
Pharma AG 




Phase II ARCA biopharma 
Table 3.  Selected aptamers in clinical trials for the treatment of disease.  
Macugen is the only FDA approved aptamer medication, but other compounds are 





3.1.2 PT-SELEX against HIV RT 
Several aptamers have been designed against HIV RT for use as ARVs.  
These aptamers are able to inhibit HIV RT reverse transcription and are inhibitory to 
viral replication in cell culture (84, 85).  The inhibition of reverse transcription is 
likely due to the structure of the single stranded nucleic acids, as well as the actual 
sequence, although structure probably plays a more significant role. 
Like other DNA polymerases, the preferred substrate for RT is double-
stranded nucleic acid with a recessed 3′ terminus (a primer-template complex).  RT 
shows a preference for DNA-primer:RNA-template over DNA:DNA hybrids, but was 
assumed, like other DNA polymerases, to not have a strong preference for specific 
sequences.  A paper published by our lab in 2006 demonstrated that HIV RT did, in 
fact, exhibit preferential binding to specific primer-template sequences (86).  By 
using PT SELEX, it was discovered that HIV RT has a strong preference for 
sequences mimicking the PPT region of the HIV genome, specifically the six 
nucleotide run of Gs at the 3′ end.  The sequences recovered from PT SELEX all had 
a 6-8 nucleotide run of Gs at the primer 3′ terminus, and this was all that was 
necessary for tight binding.  Subsequent PT SELEX experiments determined that 
other viral RTs (Moloney murine leukemia virus RT, MuLV RT, and avian 
myeloblastosis virus RT, AMV RT) also showed a similar preference for their own 






Table 4. Binding affinities of various viral RTs for their PPT and SELEX 
products.   PT SELEX with RTs from HIV, MuLV, and AMV yield tightly binding 
sequences that contain runs of Gs that match the 3′ end of the retroviral PPT.  These 
aptamers bind to their respective enzymes with affinities similar to the full PPT and 






The PPT is resistant to RNase H degradation, which allows its use as a primer 
for second strand DNA synthesis (88-92).  RNase H-resistance alone might be the 
only reason it is used as a primer by RT, but it is also a more efficient primer than 
random RNA sequences, suggesting a unique interaction with RT (93, 94).  The fact 
that RT binds this sequence more tightly than other, non-PPT sequences is therefore 
not surprising.   
Given that RT not only has a sequence-binding preference, but also one that is 
biologically relevant, it is possible that other primer-template-utilizing polymerases 
also have preferences for specific sequences. 
3.1.3 Family A DNA polymerases 
RT belongs to the broader group of enzymes called DNA polymerases, which 
are used by all cellular organisms (and many viruses) for replication of their genetic 
material.  To accomplish genome replication, these enzymes must be able to 
accurately incorporate nucleotides into new DNA.  DNA polymerases can vary 
significantly in their error rates and processivity (the average number of nucleotides 
added by the enzyme during a single binding event), as well as in their structure and 
amino acid composition.  While diverse, these enzymes can be grouped by sequence 
and structural homology into seven families (A, B, C, D, X, Y, and RT; Figure 16), 
all of which share several analogous regions that are necessary for their function (95). 
• A catalytic palm domain, which directs the phosphoryl transfer reactions 
during nucleotide incorporation.   





• A thumb domain that helps position the nucleic acid template. 






Figure 16  Crystal structures of DNA polymerases bound to DNA.  Taq pol 
(Family A) from Thermus aquaticus, gp43 (Family B) from bacteriophage RB69, and 
RT (Family RT) from HIV have analogous finger, palm, and thumb domains which 
give the enzyme a right-handed conformation.  Despite their superficial similarity, the 
finger and thumb domains between the three enzymes are significantly different in 







Figure 17: Sequence similarity of the Family A DNA polymerases. An unrooted 
phylogenetic tree shows the relationship between the amino acid sequences of various 
Family A DNA polymerases.  The scale bar indicates average number of mutations at 
a single position for that branch length.  Bacterial pols, Entamoeba pols, and pol Ns 
are primarily repair enzymes, while the phage and mitochondrial pols act as 







The Family A DNA polymerases are a family that contains numerous historic 
and commercially important enzymes (Figure 17), with representatives found in 
prokaryotes, eukaryotes, and some viruses.  These template-dependent polymerases 
are involved in both replication and repair:  
• Replicative enzymes perform both leading- and lagging-strand 
synthesis, by recruiting helper proteins and molecules to modulate 
their processivity.  Examples include the T3 and T7 bacteriophage 
DNA polymerases, as well as the mitochondrial DNA polymerase γ in 
eukaryotes (97).  Alone, T7 DNA pol can incorporate only 1-15 bases 
before dissociating from the template, but by binding bacterial 
thioredoxin it can increase its processivity to incorporate thousands of 
bases in a single binding event (98).   
• Repair enzymes are responsible for filling in the gaps generated during 
lagging-strand synthesis.  An example is the Pol I enzyme (discussed 
further below), which is found in prokaryotes such as Thermus 
aquaticus and Escherichia coli. Homologous Pol I enzymes always 
contain a 5′à3′ domain that removes the RNA primer from Okazaki 
fragments; many isolates also contain a 3′à5′ proofreading domain to 
correct misincorporated nucleotides (97). 
In 1958, Pol I was the first polymerase was discovered.  Initially isolated from 
E. coli, this 928 aa enzyme accounts for >95% of polymerase activity in the organism 
(99).  While Pol I is a weakly processive enzyme, it can only add ~20 nt before 




polymerase (this is carried out by Pol III) (100).  In addition to the polymerase 
domain, the enzyme contains both 5′à3′ and 3′à5′ exonuclease activity, giving it an 
error rate of only 10-6 to 10-8 per nucleotide (101).  Cleavage by subtilisin produces 
two fragments, the larger of which is derived from the C-terminal end and is called 
the Klenow fragment (or just Klenow) (Figure 18).  This retains the polymerase and 
3′à5′ exonuclease domains, but lacks the 5′à3′ domain.  Klenow is a commercially 
important enzyme used for numerous applications, such as creating blunt-ended 
templates (either by removing 3′ overhangs or filling in 5′ overhangs), second strand 
DNA synthesis, or preparing radiolabeled probes.  Before thermostable polymerases 
were discovered, it was also used as the enzyme for nucleotide incorporation in PCR. 
Another commercially important Pol I is the 832 aa DNA polymerase from 
the bacteria Themus aquaticus, known as Taq pol (102) (Figure 18).  As Thermus 
aquaticus lives in hydrothermal vents and hot springs, Taq pol is thermostable in 
temperatures that would denature many other proteins: its optimal temperature range 
is 75-80°C and it can withstand temperatures near boiling (at 97.5°C, the enzyme has 
a half-life of 9 min) (103).  This has made it ideal for PCR-based applications, which 
repeatedly cycle through 90°C+ temperatures (104).    Like other Pol I enzymes, it 
contains a 5′à3′ exonuclease domains, but lacks a functional 3′à5′ exonuclease 
proofreading domain.  This lack of proofreading ability gives Taq pol an error rate of 
1x104, much higher than many other Pol I enzymes (105).   
As RTs show preference for specific sequences, it is possible that other DNA 
polymerases do as well.  Given the commercial and historic importance of Klenow 






Figure 18.  Crystal structures of Klenow and Taq pol bound to dsDNA. The two 
Family A DNA polymerases, E. coli Klenow and Taq pol, both perform lagging 
strand synthesis in their respective organisms.  Klenow (A) is derived from the larger 
enzyme Pol I and lacks the 5′à3′ exonuclease activity of the full protein.  Taq pol (B) 
contains  5′à3′ exonuclease activity but does not contain a functional 3′à5′ 






Figure 19. The PT SELEX method used to generate aptamers against Klenow 
and Taq pol.  The primer is the top strand and the template is the bottom.  The initial 
fixed-region-flanked random hybrid is indicated in gray with the staggered ends 
generated by the BbsI site shown by the dotted gray line.  Fixed region B and four 
nucleotides of the random region from the primer are removed; fixed region A, 21 nt 




3.2 Materials and Methods 
 Materials 
To avoid nuclease degradation during selection, a 3′à5′ exonuclease-minus 
mutant of Klenow (exo-Klenow, containing the mutations D355A and E357A) 
purchased from New England Biolabs was used for all binding experiments, as were 
wildtype Klenow, Taq DNA pol, BbsI, and T4 polynucleotide kinase (T4 PNK).  
dNTPs were purchased from Roche Applied Sciences, radiolabeled γ-P32 dATP from 
PerkinElmer, Sephadex G-25 spin columns from Harvard Apparatus, oligonucleotides 
from Integrated DNA Technologies, and all other reagents were obtained from 
Thermo Fischer Scientific, Inc., Sigma-Aldrich Co., or VWR.  
 Preparation of random DNA:DNA hybrids for the initial SELEX library. 
 5′ radiolabeled primers were prepared as described in 2.2 Materials and 
Methods.  ~400 pmol each of radiolabeled primer (5′-
GCCTGCAGGTCGACTCTAGA-3′) and template (5′-
GCATGAATTCCCGAAGACGC(N)25TCTAGAGTCGACCTGCAGGC-3′, where N 
is any base) were mixed in a 50 µl reaction containing  50 mM Tris–HCl (pH = 8), 1 
mM DTT and 80 mM KCl.  The reaction was heated to 65ºC for 5 minutes, then slow 
cooled to room temperature to form hybrids.  The second strand was filled in by 
adding the hybrid to a 100 µl reaction containing 0.5 mM dNTPs, 6 mM MgCl2, and 
3 U wildtype Klenow and incubating for 45 minutes hours at 37°C.  The product was 
purified by running on a 12% native polyacrylamide gel and cutting out bands 
corresponding to the double-stranded hybrid.  The hybrid was eluted from the gel 




0.45 µm polyethersulfone membrane syringe filter.  The material was precipitated 
overnight at -20°C in 2 volumes of 100% ethanol and 1/10th vol of 3 M sodium 
acetate (pH = 7) (final volume ~1500 µl), then spun for 30 min at ~15,000 g to pellet 
the DNA. This was washed with 500 µl of 70% ethanol then dried in a Savant 
DNA120 speed vacuum from Thermo Fisher.   
 Oligonucleotides (Tables 5-7) were purchased and hybridized similarly, 
except at a ratio of 1:1.5 primer:template (4 pmol 32P-labeled primer:6 pmol template) 
in a 20 µl reaction. 
 Generating 3′ recessed primer:templates 
 Collected hybrids from the two reactions were incubated with 20 U of BbsI at 
37°C for 3 hours, in a final volume of 100 µl of 50 mM NaCl, 10 mM Tris-HCl, 10 
mM MgCl2, and100 µg/ml BSA.  Cut products were separated at 220 V on a 12% 
native polyacrylamide gel, extracted and precipitated as described above.  Each 
reaction typically yielded about 25-50 pm of final product.  
 Selection with exo-Klenow and Taq pol 
 For the initial selection, ~200 pmol of cleaved hybrid was incubated with 20 
pmol exo-Klenow or Taq pol for 1 hour in 100 µl of 50 mM Tris-HCl (pH = 7), 50 
mM KCl, 1 mM DTT, 10 mM MgCl2, and 50 µg/ml BSA (Klenow buffer) or 10 mM 
Tris-HCl, 50 mM KCl, and 1.5 mM MgCl2 (Taq pol buffer) at room temperature then 
run on a 12% native gel to separate bound and unbound hybrids.  Bound hybrids were 






Generation of enriched pools from selected material  
 After selection, the hybrids’ recessed ends were filled in by wildtype Klenow 
in reactions containing 0.1 U of enzyme, 50 mM Tris-HCl (pH=8) 100 µM dNTPs, 6 
mM MgCl2, 80 mM KCl and 1 mM DTT, total volume 50 µl.  After 10 min at 37ºC, 
reactions were phenol extracted and precipitated with ethanol.  Following this, the 
recovered material was ligated for 20 minutes to 5-10 fold excess of the hybrid 
duplex of 5′-ATAGCATGAATTCGCAGAAGACCC-3′ and 5′-
GGGTCTTCTGCGAATTCATGC-3′, using the Promega rapid ligation kit.  For the 
first round, the ligation was performed in a volume of 30 µl; subsequent rounds were 
performed in 10 µl following the manufacturer’s protocol. 
The entire ligation mixture was then PCR amplified by Taq pol in a 400 µl 
reaction containing 400 pmol each of the primers 5′-
GCCTGCAGGTCGACTCTAGA-3′ (32P end labeled) and 5′-
GCATGAATTCGCAGAAGACCC-3′, in Taq buffer.  The reactions were divided 
equally into 4 tubes and linear PCR amplified for 12-14 cycles of 94°C (1 min), 50°C 
(1 min) and 72°C (1min), followed by a final 5 min extension at 72°C.  This material 
was then combined, BbsI digested and purified as above.  This selection process was 
repeated 6 times for both Taq pol and exo-Klenow, with subsequent rounds using 
~1/20th the enzyme (mole:mole) of the recovered material, until no increase in 
binding was noticed between rounds.  After round 2, 1/5 of the material was also 
saved from each round for use in Kd determinations.  After reaching round 7, material 
from each selection pool was inserted into a vector and cloned into bacteria using the 




manufacturer’s instructions.  Isolated colonies were grown overnight in 3 ml of 50 
µg/ml ampicillin-LB broth. Insert-containing plasmids were purified using the Qiagen 
Spin Miniprep kit and sequenced by GeneWiz.   
 Determination of Kd by gel shift 
 Material from selection rounds and purchased oligonucleotides were 5' end-
labeled on the primer and hybridized as described above.  These were mixed with 
various amounts of either Taq pol or exo-Klenow at a final concentration of 2 or 20 
nM final substrate concentration, respectively, (binding affinities for the pools from 
each round and the random substrate were determined at a concentration of 20 nM; 
analysis of the constructures was performed at a final substrate concentration of 2 
nM) in either Klenow or Taq pol buffer.  The enzyme concentrations were 0, 1.1, 3.1, 
6.3, 12.5, 25, and 50 nM Taq pol and 0, 25, 50, 100, 200, 400, and 800 nM exo-
Klenow, unless otherwise indicated.  The enzymes and hybrids were incubated for 5 
min at room temperature and then run at 110 V on a 7% polyacrylamide native gel.  
The products were visualized on a FLA-7000 phosphoimager (Fujifilm) and the 
amount of product shifted vs. unshifted was quantified with Multi Gauge software.  
The Kd was determined by plotting the ratio of material shifted 
([shifted]/[shifted+unshifted]) vs. the concentration of the enzyme and fitting the data 
by nonlinear least square fit to the quadratic equation: [ED] = 0.5 ([E]t + [D]t + Kd) − 
0.5 (([E]t + [D]t + Kd)2 − 4 [E]t[D]t)1/2, where [E]t is the total enzyme concentration 






 Mutations of selected sequences 
 To test the importance of specific nucleotides for tight binding in the selected 
primer-template aptamers, mutational analysis was performed by substituting AàC, 
Cà, GàT, and TàG.   See Table 5 for construct details. 
3.3 Results 
3.3.1 SELEX results for exo-Klenow 
After seven rounds of SELEX, the enriched pool bound the enzyme 5x better 
than a random pool (Kd of 90±10 nM vs. >500 nM), suggesting that it contained high-
affinity sequences (Figure 20).  The pool was clonal sequenced and twelve isolates 
were recovered, of which eleven showed significant similarity (Figure 21B).  
Interestingly, these eleven sequences contained a second BbsI site in an orientation 
opposite to the engineered site in the primer region (see Figure 21A).  Due to 
incomplete cleavage by the restriction enzyme, this allowed a nick on each strand that 
resulted in a 9 nt overhang on the 5′ end of the template, instead of the intended 4 nt 
overhang (generating 36 nt primer/45 nt template pairs).  Subsequent testing revealed 
that reducing the length of the overhang by more than 3 nt significantly disrupted 
binding (Table 5), suggesting a strong selective pressure for the location of this 
second BbsI site.   
Intriguingly, seven of these sequences contained a region identical to T7 
RNAP consensus promoter sequence (bases -6 to + 1, called the T7Pcore), while 
three others contained only a single nt difference in that region. In the phage RNAP 
promoters, this region is highly conserved between different RNAPs (a single base 




stranded bubble forms for the initiation of transcription.  The sequence selected by 
Klenow contained four of these bases in the duplex region and three bases in the 
single-stranded template overhang of the primer-template hybrid.  A consensus 
primer-template sequence was selected for subsequent testing (named Exo-Kl) to 
determine which bases contribute most to this selective binding.  This construct 
bound with a Kd of ~150 nM, higher than the round 7 material, indicating that there 







Figure 20. Gel shift comparison between the starting pool and round 7 pool from 
Exo-Klenow SELEX. A) The starting pool of random hybrids was bound by exo-
Klenow with a Kd greater than 500 nM.  Klenow concentrations were 0, 25, 50, 100, 
200, 400, and 800 nM.  B) By round 7, the enzyme bound the pool with a Kd of 
90±10 nM, indicated that the pool had been enriched for sequences that bound the 
enzyme.  Concentrations used for this assay were 3.1, 6.25, 12.5, 25, 50, 100, 200, 





Figure 21. Primer-template sequences selected by Exo-Klenow SELEX.  A) The 
original hybrids and intended BbsI cut site (which generates 41:45 nt 
primer:templates) and the second selected cut site (which yields 36:45 nt primer 
templates).  B) The eleven sequences isolated from round seven containing a portion 
of the T7 promoter region, aligned using MacVector.  Sequences are from the primer 
strand and the nine bases corresponding to the single-stranded template overhang are 





3.3.2 Determination of sequences important for exo-Klenow binding 
 Mutational analysis was performed on the representative sequence (see Table 
5 for constructs and binding affinities) to determine which bases were most 
responsible for the specific binding of exo-Klenow.  In addition to constructs with 
template truncations (described above) which revealed that the enzyme’s preference 
for nine nt overhangs, two other major types of mutations were made: base 
substitutions and shifted sequences within the context of the duplex:single-stranded 
primer-template.   
Modifying the seven bases that made up the T7Pcore disrupted tight binding 
to exo-Klenow; as this sequence was found in most of the recovered sequences, the 
result is not surprising and implies that that these bases contribute significantly to the 
specific interaction with the enzyme.  Of the T7Pcore sequence, it appears that only 
the four bases in the duplex region are important: modifying the nine nt single-
stranded template overhang sequence (which contains three nt of the T7Pcore) did not 
significantly alter enzyme binding, despite being highly conserved among recovered 
sequences.  Modifying the bases 5' of the T7Pcore also reduced binding, although the 
defect was not as severe as when the T7Pcore was modified. Together, these results 
suggest that the four bases of the T7Pcore in the duplex region are the major 
contributors to tight binding but are aided by sequences upstream.  This agrees with 
the observation that the region of conservation among these sequences is larger than 
just the T7Pcore.  
To determine if the context of the sequence relative to the primer terminus 




sequences were shifted further in (-1, -4, -8) or out (+1) of the duplex region.  Only 
the -1 shift (which contained five bp of the T7Pcore in the duplex region and two nt 
in the single-stranded region) was tolerated; other shifts were deleterious to binding, 






Table 5. Kd of  exo-Klenow for the Exo-Kl sequence and modified constructs. 
Modified bases are underlined. An (*) indicates the average of two independent 
experiments.  A Kd determined from a single experiment is prefixed with (~).  Three 
types of mutations were tested for their effect on exo-Klenow binding: 1) the length of 
the template, 2) the location of the conserved T7Pcore relative to the primer terminus, 
and 3) mutations of the conserved nucleotide sequences.  The only mutations that 
were relatively tolerated were a single nucleotide truncation from the template and 
shifting the sequence -1 from the primer terminus.  All other mutations produced 





Figure 22.  Gel shift with the Exo-Kl construct and a modified version, which has 
the T7Pcore replaced. A) The Exo-Kl construct is bound by exo-Klenow with a Kd 
of ~150 nM.  B) Modifying the template overhang diminishes binding but does not 
full disrupt it.  C) Modifying the T7Pcore significantly prevents binding of the 
enzyme to the primer-template.  In A and B, the concentration of exo-Klenow is 0, 25, 
50, 100, 200, 400, and 800 nM.  In C, the concentration is 0, 200, 400, and 800. 





3.3.3 SELEX results for Taq pol 
 To determine if other Family A DNA polymerases preferentially bound 
primer:template sequences, SELEX was carried out for seven rounds using Taq pol.  
From this pool twelve sequences were isolated, out of which two sequence motifs 
were identified (see Figure 23).  A consensus sequence from each motif group 






Figure 23.  Sequences recovered from round seven of Taq pol PT SELEX.  
Nucleotides that match the consensus, located beneath each alignment, are 
represented by a dot.  Of the twelve sequences isolated (A), two general motifs were 
observed.  Group 1(B) contained a region that matched the initiation domain of the 
T3 RNAP promoter.  Group 2 (C) did not contain a recognizable biologically relevant 





Figure 24.  Gel shift of Taq1 and Taq2 constructs, as well as a random pool, by 
Taq pol.  The constructs were derived from the consensus sequences for the two 
observed motifs isolated from round seven.  Taq1 is bound by Taq pol ~8x better, 
while Taq2 is bound 20x more tightly.  In each gel, the concentration of Taq pol is 0, 






The five Taq1-like sequences were identical except for a single nt substitution in one 
isolate.  All contained a region that, like the sequences selected by exo-Klenow, 
contained bases -6 to +1 of the T3 RNAP promoter region (which is identical to the 
T7 promoter sequence at those positions except for a single nt at -2, see Table 8), 
called the T3Pcore.  Unlike the exo-Klenow-derived sequences, this region was 
contained fully within the duplex DNA (4 bp upstream from the primer terminus).  
Taq1 primer-template hybrids bound the enzyme with a Kd of 8 nM, 8x more tightly 
than the random pool. 
 The three non-T3-like sequences contained an eight bp conserved motif 
completely unlike that of the Taq1 sequences and with no known similarity to any 
biologically relevant motifs. A primer-template synthesized with the Taq2 consensus 
sequence bound the enzyme with a Kd of 3 nM, almost 3x more tightly than Taq1 and 
>20x that of the random pool. 
3.3.4 Determination of sequences important for Taq pol binding 
Much like with the sequences derived from exo-Klenow SELEX, mutational 
analysis demonstrated that the location and context of each sequence was necessary 
for tight binding (see Table 6 for constructs).  To see if the T3Pcore was responsible 
for the affinity of Taq pol to the Taq1 motif, a construct was created with 
substitutions at every nucleotide except the T3Pcore.  This construct suffered from 
defects in binding (~13 nM, compared to 8 nM for Taq1) but still bound ~4x better 
than the random pool, indicating that the T3Pcore was an important factor in the 
enzyme’s affinity for the substrate but that other sequences surrounding this region 




T3 RNAP promoter as poorly as it did a random pool, suggesting that a construct with 
the entire promoter sequence is in a conformation that disrupts Taq pol binding, 
despite the presence of the T3Pcore).  By mutating four bp pieces of the T3Pcore, it 
was learned that the bases matching from -3 to +1 in the T3 RNAP promoter were the 
largest contributors to tight binding (4 nt modification B in Table 8); mutation of 
these bases disrupted binding while mutating the -7 to -4 bases (4 nt modification A) 
did not have an effect.  Intriguingly, sometimes small changes to the T3Pcore were 
more deleterious to binding than large ones: a single bp change of the -2 base (to 
mimic the T7 promoter sequence, Table 8) completely disrupted binding.  Like exo-
Klenow, the enzyme did not tolerate shifting the context of the sequence relative to 






Table 6.  Taq1 constructs generated for mutational analysis of the nucleotides 
important for Taq pol binding to primer-templates. Modified bases are underlined.  
An (*) indicates the average of two independent experiments.  A Kd determined from 
a single experiment is prefixed with (~).  Most modifications negatively impact 
binding; the best tolerated mutations were those which were outside of the bases 
underlined in ‘4nt modification B’, suggesting that these bases are the most important 




Table 7. Taq2 constructs generated for mutational analysis of the nucleotides 
important for Taq pol binding to primer-templates.  Modified bases are 
underlined.  An (*) indicates the average of two independent experiments.  A Kd 
determined from a single experiment is prefixed with (~).  All of the constructs 






Unlike Taq1, all modifications of Taq2 disrupted binding.  Modification of the 
8 bp region found in all three sequences (called the 8 bp core) reduced binding ~8x, 
as did modification of the bases upstream of this region.  In contrast to Taq1, the 
bases on the overhang had a substantial impact on binding (‘Modified non-core 
nucleotides’ vs. ‘modified non-core/non-overhand nucleotides’); all constructs with 
modified overhangs showed binding similar to the random pool, suggesting that Taq 
pol interacts with this substrate differently than Taq1. 
3.3.5 Enzyme specificity to selected sequences 
 Though the sequences selected by exo-Klenow and some of those selected by 
Taq pol contained regions identical to the T7-like RNAP promoters, exo-Klenow was 
unable to bind the Taq1 sequence with a higher affinity than for the random substrate 
(>800 nM).  Likewise, Taq pol only bound the Exo-Kl substrate with a Kd of ~50 nM.  
Whether this was due to sequence differences or the different location of the T7/T3 
promoter core within the primer-template (spanning the primer terminus in Exo-Kl vs. 
four bases upstream from the terminus in Taq1) was not determined.   
3.4 Discussion 
The single subunit RNA pols (RNAPs) are a group of enzymes found in 
bacteriophages (such as T3, T7, and SP6), chloroplasts, and mitochondria that are 
structurally homologous to Family A DNA pols.  Like the Family A pols, they 
contain finger, thumb, and palm domains that use a two-metal ion cofactor for 
nucleotide incorporation off of a DNA template.  However, unlike the template-




sequence to bind to the DNA template and initiate RNA transcription.  In the T7-like 
phage RNAPs, this sequence is sufficient for the enzyme to perform binding, melting, 
and initiation; mitochondrial and chloroplast RNAPs also require cellular factors for 
transcription.  This promoter is highly specific for each enzyme and there is 
significant sequence variation within the group (Table 8).  The phage RNAP 
promoter sequences from T3, T7, and SP6 are closely related with nearly identical 
binding and initiation domains.  A single nucleotide triplet (-12 to -10 from the 
transcription start site) is what distinguishes between the sequences and is sufficient 
to prevent non-specific RNAP binding; this is detected by a specificity loop on the 







Table 8.  Consensus sequences for the promoters of the single-subunit RNA 
polymerases.   (Above) An annotated consensus sequence for the T7 RNAP.  Bases -
17 through -5 (dashed line) are important for T7 RNAP binding; bases -4 through +6 
(dotted line) are involved in initiation of transcription and are melted open by the 
enzyme.  The first base transcribed (+1) in bold and underlined.  These regions are 
the same in other phage promoters (such as T3 and SP6) (108-111). (Below) 
Consensus sequences for RNAP promoters among phage and eukaryotes.  The first 
base transcribed is underlined in each sequence.  The phage RNAPs do not require a 
transcription factor for initiation of transcription, while the RNAPs from eukaryotes 






It is likely that the regions of structural similarity between the T7-like RNAPs 
and the Family A DNA pols are responsible for the shared attraction to these 
promoter sequences. While the enzyme amino acid identities vary significantly (for 
example, Klenow and T7 RNAP share only 8 aa in the palm domain, corresponding 
to two conserved Asp-containing motifs A and C, which are found in most 
polymerases), the enzymes are all right-handed polymerases with homologous palm 
and finger architecture (though phage RNAPs contain additional structures not found 
in Klenow or Taq pol) (113). 
Studies of how Klenow interacts with template stands suggest that the enzyme 
only has contact with the phosphate backbone of the nucleic acid (106), which has 
been thought to preclude sequence-specific attraction.  Our results contradict the idea 
that Klenow lacks sequence specificity, as we have demonstrated that the sequence of 
a primer-template promotes significant differences in binding affinity.  Still, it is 
possible that the structure of the selected primer-template is what is responsible for 
the tight binding and not base-specific interactions with the enzyme.  
Previous reports have demonstrated that the T7 RNA promoter has an intrinsic 
bend of 10 degrees.  When bound to the enzyme, this bend increases to 40-60 degrees 
and is centered around the -2 to +1 region of the promoter.  It is possible that the 
intrinsic bend on the promoter aids in binding both to the T7 RNA promoter as well 
as to Taq pol and Klenow, which both have been observed to induce significant bends 
in their substrates upon binding (120 degrees (114) and 80 degrees, respectively).  
This seems most likely for the Taq pol-selected aptamers, as the promoter-like 




unlikely to explain the preferential binding of Klenow to these sequences, as they are 
partially single-stranded at this region.   
 This location disparity is possibly due to the differences between Klenow and 
Taq pol: despite their structural similarity, Taq pol and the full E. coli pol I enzyme 
contain only 49% protein sequence identity (115).  A significant difference between 
the two enzymes is the presence of 3′->5′ exonuclease activity in Klenow.  Structural 
analysis of Klenow bound to primer-template DNA reveals that the primer-template 
can adopt a ‘frayed open’ conformation that allows the primer strand to interact with 
the exonuclease domain while the template is in the pol domain (116).  In this, the 
three terminal 3′ bases of the primer are single stranded and ‘scrunched’ into the 
exonuclease domain.  A shuttling mechanism is proposed to move the primer 
terminus from the exonuclease region to the polymerase domain for catalysis.  This 
allows the enzyme to perform both nucleotide addition and excision repair without 
dissociation from the template.  It is tempting to suspect that the reason the Klenow-
selected T7-like region is located partially on the overhang is to promote unwinding 
that allows the 3′ primer terminus bases to interact with the exonuclease domain in 
the frayed open conformation while the template binds to the polymerase domain.  
Reports have demonstrated that Klenow interacts with at least the first four bases past 
the polymerase site (117); this agrees with our results suggesting an affinity for single 
stranded templates that are at least six bases long.  In contrast, Taq pol shows no 
specific affinity for single-stranded regions, explaining why the conserved T7-like 




To test this hypothesis, it would be possible to use circular dichroism (CD) to 
determine the conformation of the primer-template SELEX sequences when 
associated with their enzymes.  Structural studies have found that primer-template 
DNA is in B-form when bound in the Klenow exonuclease domain; for both Klenow 
and Taq pol, duplex DNA is in A-form when bound in the polymerase domain.  CD 
can distinguish between these forms and would allow an estimation of the nature of 
the selected primer-templates when bound to both Klenow and Taq pol. 
3.5 Conclusions 
 Despite the divergent functions of the single subunit RNAPs and the Family A 
DNA polymerases, two Family A DNA polymerases have strong affinities for 
sequences containing portions of the RNAP promoters.  It is possible that this affinity 
is from a common ancestor that has been retained in the divergent enzyme groups and 
was later exploited by RNAPs to use as their promoter sequence.  It is also possible 
that the nature of the DNA pol domains contain this affinity as a byproduct of their 
catalytic nature.  Unlike the PPT sequence selected by RT, which serves in vivo to 
promote binding of RT to the primer-template in the correct orientation for DNA 
synthesis (118-121), these sequences do not have a known biological significance for 
the DNA pols and determining if one exists will require more research.  One possible 
method would be to measure over- or under-abundance of the SELEX motifs relative 
to a random sequence of the same length in the E. coli or T. aquaticus genomes, 
which would suggest a selective pressure for the number of times that sequence is 
present.  The preferential location of the sequences on either the lagging or leading 




biological relevance.  For example, if the T7Pcore sequence is only found on the 
leading strand in E. coli and is significantly underrepresented on the lagging strand 
(where Klenow/E. coli pol I performs DNA synthesis), then this would suggest that 
the T7Pcore sequence is somehow inhibitory to the enzyme’s function and the 
genome is under selective pressure to not contain that sequence.  Conversely, 
overabundance of the sequence would suggest that perhaps the enzyme is recruited to 
these locations for an unknown purpose. 
 It may be possible to exploit these preferences to develop new technologies 
based on the enzymes’ binding affinities to specific primer-template sequences.  Taq 
pol binds sequences with high affinity at temperatures between 40-50°C; this binding 
decreases when the enzyme reaches its optimal temperature for extension (115).  
Potentially, a primer-template containing one of the tight-binding sequences could be 
used as an inexpensive ligand to temporarily inactivate Taq pol before PCR, similar 
to the current antibody-based Hot Start PCR technology that is used to prevent 
extension of non-specifically annealed primers at low temperatures, such as during 
reaction preparation.  Taq pol would stay bound to the primer-template through the 
first round of extension, whereupon it would extend the primer to create a fully 
duplex hybrid.  As the specific affinity of Taq pol for these primer-template 
sequences is dependent on both single and double-stranded regions, this extension 
would essentially inactivate the primer-template and free the enzyme for subsequent 
amplification of the intended target.   
 Troublingly, if these sequences promote Taq pol extension (or conversely, if 




next-generation sequencing data.  In a situation where the occurrence of this T7 
RNAP promoter-like sequence is limiting relative to the number of Taq pol 
molecules, the affinity of the enzyme for this sequence will likely have little effect on 
the efficiency of extension.  However, if the relative abundances are reversed, then a 
preferential binding of Taq pol to promoter-like elements could result in artificially 
high quantities of these sequences being amplified.  It is possible to test this by 
engineering a plasmid vector that contains both a tight-binding and poor-binding 
sequence then PCR amplifying using equimolar concentrations of both primers.  
Assuming no extension preference, both sequences will be amplified equally; 
however, if there is a preference then it would be detectable by measuring the relative 
abundance of the products.   
 Despite issues raised by this discovery, the knowledge that Klenow and Taq 
pol bind to T7 RNAP promoter-like sequences remains intriguing.  This adds to the 
body of evidence that the Family A DNA polymerases share a common ancestor with 
single subunit RNAPs, despite their extreme evolutionary divergence among viruses, 
prokaryotes, and eukaryotes.  The fact that this affinity has been retained through 
millions of years of evolution suggests a selective pressure for its retention, whether 
through biological relevance (as in the case of the RNAP promoter) or some 







Chapter 4: Modulation of Reverse Transcription in vivo 
 
4.1 The effect of cellular small molecules on reverse transcription  
4.1.1 Introduction 
Research into the mechanics of retroviral reverse transcription has been aided 
by the existence of cell-free in vitro assays, which facilitate replicable studies of 
individual steps in the reverse transcription process and are an attractive alternative to 
cell-based assays as they permit analysis of conditions that might otherwise be 
impossible to obtain in vivo.  Reverse transcription assays using purified RT 
(described in 2.2 Materials and Methods) have been optimized for the speed of 
nucleotide incorporation by the enzyme; while these conditions promote efficient 
DNA synthesis by RT, they fail to completely mimic the natural environment of the 
cell where reverse transcription would occur during the viral lifecycle.  For instance, 
many RT assays use Mg2+ and dNTP concentrations (4-6 mM and 50-100 μM, 
respectively) that are greater than the concentrations found in cells (0.25 mM-2 mM 
Mg2+ and 5 μM dNTPs in T cells (122)).  These differences can significantly impact 
the behavior of HIV RT: for example, extensions performed with more physiological 
concentrations of Mg2+ have shown reduced RNase H cleavage and polymerase 
pausing, which led to increased enzyme processivity (60).  In addition to Mg2+ and 
dNTPs, the cytosol also contains other small molecules (rNTPs, amino acids, cations, 
etc.), some of which have been implicated in affecting the behavior of HIV RT (e.g. 




all of these components affect reverse transcription, it is clear that at least some do 
and their exclusion from cell-free RT assays could distort the results of these studies.  
It would be useful to evaluate these compounds for their role in modulating the 
behavior of HIV RT, which would permit researchers to create more life-like cell-free 
assays with components that are important for reverse transcription.  Unfortunately, 
most protocols used to isolate various cell components require buffers or extraction 
steps that make the resulting supernatant unusable for direct testing in reverse 
transcription assays.  To address this, I developed a minimally-invasive protocol for 
extracting the small molecular fraction (molecules and proteins <3 kDa, which 
includes the dNTPs and Mg2+ necessary for extension by RT) from cells for use in 
driving reverse transcription in cell-free assays. 
4.1.2 Materials and Methods 
Jurkat cells, an immortalized T cell leukemia line, were grown in RPMI 
supplemented with 10% heat-inactivated fetal bovine serum and 100 units of 
Penicillin/0.1 mg/ml of Streptomycin. 1 x 108 cells were harvested at a density of 5 x 
105 cells/ml and pelleted for 5 min at 4°C and 250 g to remove propagation medium.  
To remove extracellular components, the cell pellet was washed by resuspension and 
then centrifugation (as before) twice in buffers with decreasing ionic strength: first, in 
1 ml of ice cold 1x PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 2 mM 
KH2PO4) then in 0.1x PBS.  Following the removal of the supernatant, the cells were 
resuspended in 1 ml of Milli-Q water and allowed to swell on ice for 10 minutes, after 




The nuclear fraction removed by pelleting at 3300 g for 15 minutes in 4°C and 
the remaining cytosolic supernatant was passed through a 3 kDa molecular weight 
cutoff filter (Amicon Ultra-0.5 mL centrifugal filter, pre-washed with 500 µl 0.1 N 
NaOH, then 500 µl of Milli-Q water to remove glycerine).  The collected filtrate, 
referred to as the small molecular fraction (SMF), was then volume-correct by 
vacuum drying on low heat to one half of the estimated volume of the cytosol of 1 x 
108 Jurkat cells (0.8 picoliters/cell with the cytoplasm occupying about 80% of the 
total cell volume, calculated from (125)), creating a 2x concentration SMF.  During 
volume correction, SMFs were never allowed to completely evaporate. 
Reverse transcription assays were performed using a modified version of the 
protocol described in 2.2 Materials and Methods: extension was performed with 50 
nM RT on a 100 nt ssDNA from the gag-pol region of the HIV-1(NL43) genome, 
which was hybridized 1:1 to a 32P-radiolabeled 20 nt primer (4 nM final).  Final 
reactions were carried out in 15 µl and contained 10 mM Tris-HCl (pH=8), 80 mM 
KCl, and varying concentrations of 2x SMF, dNTPs, and MgCl2 as indicated.  
4.1.3 Results and Discussion 
 In reactions containing only the SMF and no exogenous Mg2+ or dNTPs, RT 
was able to carryout efficient extension of the template, demonstrating that the SMF 
contained all of the components necessary for catalysis.  While the speed of extension 
was qualitatively similar to control reactions that contained physiological 
concentrations of Mg2+ (1 mM) and dNTPs (1 or 5 µM, representing the lower and 
upper estimates for cellular dNTP concentrations), the SMF-driven reactions were 




MgCl2 and 1 µM exogenous dNTPs to a 5 µl SMF reaction resulted in extension that 
was as robust as the control, suggesting that the slower extension speed was due to 






Figure 25. HIV RT extension of a ssDNA template stimulated by SMF.   3 (A) 
and 30 (B) minute extension reactions with known concentrations of MgCl2 and 
dNTPs, SMF plus exogenous dNTPs (1 or 5 µM) and 1 mM MgCl2, or SMF only.  
SMF contents are able to drive RT extension, although extension is slower than in 
reactions with estimated physiological concentrations of MgCl2 and dNTPs.  





It is most likely that the loss of cytosolic components occurs during the initial 
washes of the cell pellet, particularly during the hypotonic 0.1x PBS wash.  
Unfortunately, replacing the hypotonic wash with a second isotonic wash resulted in 
severe extension inhibition, most probably because excess PBS remaining on the 
pellet was excessively concentrated during the volume correction of the SMF.   
Instead of extracting the SMF, it may be necessary to construct an artificial 
SMF using known concentrations of cellular components.  This would allow for 
testing the compounds that affect characteristics of reverse transcription (speed of 
catalysis, fidelity, recombination, etc.) and could be used to improve existing RT 
assay protocols. 
4.2 Inhibition of HIV replication in cell culture by aptamers against HIV RT 
4.2.1 Introduction 
As discussed in 3.1.2 PT-SELEX against HIV RT, numerous nucleic acid 
aptamers have been designed against HIV RT using SELEX and other methods.  
Unfortunately these aptamer inhibitors face many challenges for use as theraupeutics, 
namely in their ability to enter host cell and resist degradation.  Uptake of nucleic 
acids by cells is limited and aptamers are easily degraded by host nucleases (reviewed 
in (126)).  Off-target effects and cytotoxicity are additional concerns; the Toll 
pathway can be activated by foreign nucleic acids, inducing interferon (IFN) 
production (127). 
Fortunately, many of these problems can be avoided. To protect against 
nucleases and degradation, aptamers can be made with modified sugar and 




aptamer entry, such as attaching aptamers to small protein anchors 128 or microsphere 
containers (129) which can more easily cross the cell membrane.  Studies have also 
demonstrated that viral infection can promote cellular uptake of naked aptamers (130, 
131), which suggests another promising avenue of directed anti-HIV aptamer entry.   
Using DNA hairpin aptamers generated by PT SELEX against HIV RT (132), 
I began researching a new method of delivering aptamers using a DNA dendrimer 
container developed by the Muro lab (133) (Figure 26).  These dendrimers contain 
multiple branched DNA modules made up of central double-stranded regions and 
four single-stranded arms, which can be coupled to antibodies.  The antibodies are 
targeted against the cargo and also endocytic receptors on cells for delivery of cargo 
by cellular uptake.  Inside the endosome, the low pH causes structural destabilization 
of the DNA, which releases the cargo and ultimately leads to escape.  My research 
focused on determining if the dendrimers alone affected HIV replication or altered 
how the aptamers inhibited HIV; the dendrimers were not modified to carry the 





Figure 26.  Structure of the nucleodendrimer.  The dendrimer is made of DNA 
modules with branched ssDNA arms that can be attached to antibodies targeting the 







4.2.2 Materials and methods 
 Aptamers 
 
 The inhibitory hairpin aptamers (thioaptamer and 2,4 O-methyl aptamer, 
Figure 27) used in this study were initially generated using PT SELEX against HIV 
RT as described in (132). To protect against nuclease degradation, the 38 nt 
thioaptamer was engineered with three most 5’ bases and the three bases predicted to 
be single stranded in the hairpin loop were substituted with thionucleosides.  The 2,4 
O-methyl aptamer is a second 38 nt hairpin aptamer (with a different hairpin 
sequence than the thioaptamer) which contains O-methyl bases at positions 2 and 4 






Figure 27. Aptamers used to test inhibition of HIV replication in cell culture.  
The 38 nt thioaptamer contains thionucleosides(*) to prevent nuclease degradation.  
The 2,4 O-methyl aptamer has O-methyl rNTPs (*) in the hairpin to take advantage of 
RT’s increased affinity for substrates with ribonucleoside bases at those positions 































































































Cell culture and HIV infection 
 
Infection studies were performed in TZM-bl cells, a HeLa-derived cell line 
which expresses the CD4 receptor and CCR5 coreceptor to permit HIV infection.  
This cell line contains a luciferase gene that is controlled by an upstream HIV-1-
derived tat promoter, which is activated by HIV infection. Cells were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum and 100 units of Penicillin/0.1 mg/ml of Streptomycin.  
Wildtype HIV-1 was produced by transfection of 293T cells with the 
infectious clone pNL4-3.  Pseudotyped HIV-1 was produced by cotransfection of 
pNL4-3/kfs (a plasmid which contains a frameshift mutation in the env gene, 
preventing production of gp120) and p-CMV-VSV-G (which produces the vesicular 
stomatitis virus G glycoprotein to serve as a replacement envelope protein that does 
not require a receptor for cellular entry). 
24 hours before infection, cells were plated on opaque white 96-well plates at 
a 2x104 cells/ml in 200 µl media.  After 24 hours, the media was changed cells were 
infected with NL4-3-derived HIV at an MOI of 0.005 in the presence of aptamer (2 
µM, unless otherwise stated), antibody-coupled dendrimers (1x concentration at100 
ng/ml of DNA, 5 µg/ml antibody), antibody alone (5 µg/ml antibody), or antibody-
coupled nanoparticles (6.8 x 1010 particles/ml, 5 µg/ml antibody).  To measure 
infection, a luciferase assay was performed 24 hours post-infection using the 
briteliteTM kit from Perkin Elmer and following manufacturer instructions.  Relative 
Luciferase Units (RLUs) were determined using the Centro XS3LB 960 Microplate 




reported as a percentage of an HIV-only infection.  Each condition was assayed in 
triplicate. 
The dendrimers, antibodies, and nanoparticles were prepared and provided by 
the Muro lab, using the protocol in (133).  Dendrimers targeted to TZM-bl cells were 
coupled to a monoclonal anti-transferrin receptor antibody, while non-targeted 
dendrimers were coupled to a rat anti-mouse IgG antibody. Nanoparticles were 
polystyrene coated with the anti-transferrin receptor antibody. 
 
4.2.3 Results 
Inhibition of HIV replication by the thioaptamer 
 
The thioaptamer strongly inhibits HIV replication in a dose dependent 
manner.  The highest concentration tested, 2 µM, reduces infection to ~10% of 
uninhibited control infections.  This inhibition is unlikely to be due to a block at 
entry; both wildtype and pseudotyped HIV were inhibited by the thioaptamer, even 







Figure 28. Inhibition of HIV replication by the thioaptamer.  Only 0.5 µM is 
required to reduce HIV infection to ~20% of control and 2 µM reduces infection to 
~10% of an uninhibited infection.  This inhibition is not due to the aptamer 
preventing the virus from interacting with CD4 or entering the cell; receptor-
independent pseudotyped HIV is also inhibited by the aptamer, as are both viruses 



























































Co-infection of aptamers and dendrimers 
 
The dendrimers were tested for their effect on cell growth and inhibition of 
HIV replication, both in the presence and absence of the thioaptamer (Figure 29).  
Cell density was measured 24 hours after the addition of the dendrimer; while there 
was variation in the cell counts, no significant changes were observed.  Some 
inhibition of infection was observed with the addition of the dendrimers.  Whether 
this is due to direct blocking of HIV or some other interaction is unknown.  No effect 







Figure 29.  The effect of varying concentrations of dendrimers on HIV infection 
and cell growth in the presence and absence of thioaptamer.  Dendrimers mildly 
inhibit HIV infection in a dose dependent manner and do not block the inhibitory 
effect of the thioaptamer (2 µM).  At 24 hours post addition, the dendrimer had no 







The thioaptamer’s strong inhibitory effect on HIV replication makes observation of 
minor changes in inhibition difficult to observe.  To test if the dendrimer could 
potentially increase the inhibitory effect of a non-cargo aptamer (perhaps reducing the 
concentration of aptamer necessary to reach therapeutic doses), we used the 2,4 O-
methyl aptamer, which is only moderately inhibitory of infection and would allow the 
observation of both positive and negative effects by the dendrimers.  Unfortunately, 
the dendrimers did not significantly alter the inhibitory effect of the aptamer and no 








Figure 30. Inhibition of HIV replication by the 2,4 O-methyl aptamer in the 
presence and absence of the dendrimer.  As the 2,4 O-methyl aptamer is less 
inhibitory than the thioaptamer, changes in inhibition are easier to visualize.  
Dendrimers are inhibitory of HIV infection on their own, but do not enhance or 






As it was possible that the targeted nature of the dendrimers somehow blocked 
HIV entry into the cell, the individual components of the dendrimers were tested for 
their inhibitory effect on HIV replication (Figure 31).  Dendrimers were prepared 
which contained an antibody (rat anti-mouse IgG) that was not targeted to the TZM-
bl cells used in the assay.  The anti-transferrin receptor antibody was also tested for 
its inhibitory effect, as were nanoparticles coated with the antibody (to determine if 






Figure 31.	  The effect of various dendrimer components on HIV infection.  The 
inhibitory effect of the dendrimers on HIV infection is not due to interference by the 
anti-transferrin antibody or the composition of the dendrimers themselves.  Non-
targeted dendrimers (containing rat anti-mouse IgG) also inhibited HIV infection, as 
did nanoparticles complexed with the anti-transferrin antibody.  The antibody alone 




























The antibody alone did not alter HIV infectivity, but the targeted and non-
targeted dendrimers, as well as the targeted nanoparticles, inhibited the virus.  This 
suggests that the dendrimers themselves are somehow inhibitory of infection but not 
due to their interaction with the targeted cell.  Potentially, trace reagents used in the 
preparation of the dendrimers and nanoparticles remain present and inhibit HIV, but 
this is undetermined.  
4.2.4 Discussion 
The DNA dendrimers we tested do not appear to have any negative effects on 
cell growth or viability, nor do they block the action of the inhibitory aptamers.  
While they unfortunately do not have a synergistic effect with the aptamers (at least, 
when the aptamers are not attached as cargo), they are mildly inhibitory of HIV 
infection on their own.  These results suggest that the dendrimers are a good 
candidate for use as cargo containers for anti-HIV aptamers.  Whether they will 
increase the inhibitory effect of the aptamers (potentially lowering the amount 
necessary to reach therapeutic concentrations) remains to be seen through future 
research but these preliminary results are promising. 
4.3 Conclusions 
Often, translating in vitro research to a cellular infection encounters problems.  
RT assays with purified enzymes have been helpful in understanding the behavior of 
the enzyme during reverse transcription, but the unnatural conditions imposed by 
these reactions have produced results that, in some cases, vary wildly from the reality 




under conditions that are impossible or impractical to achieve in cells.  One way of 
reducing the discrepancies between in vitro and in vivo results would be to create a 
more lifelike assay, which incorporates cytosolic molecules that have an affect on 
HIV replication.  I have attempted to create a protocol for extracting these molecules 
for use in RT assays, but unfortunately have been unable to prevent the loss of crucial 
components such as dNTPs.   
SELEX is a versatile and powerful tool for generating inhibitory aptamers 
against viral protein targets such as HIV RT, however, they face severe difficulties in 
being used as cellular therapeutics: delivery of the aptamer into the cell, in particular, 
is a major hurdle.  DNA dendrimers present an exciting opportunity to reduce the 
concentration of aptamers necessary for inhibition of HIV RT and could possibly be 







Chapter 5: General Conclusions 
Polymerases are integral to the lifecycle of all organisms and we have adapted 
them for use in numerous biotechnologies (102, 104, 135).  Despite decades of 
research, fundamental information remains to be uncovered about their behavior. 
In Chapter 2, I demonstrated that the behavior of HIV RT can be 
fundamentally altered by the cation composition during reverse transcription and 
dsDNA replication.  Concentrations as low as 5 µM Zn2+ were able to slow the 
enzyme’s nucleotide incorporation, even when the concentration of Mg2+ was 2 mM.  
Despite the potent inhibition by Zn2+ of reverse transcription, this divalent cation was 
also able to promote DNA synthesis from both RNA and DNA templates and at 
optimal concentration of 400 µM, which is 1/8th the optimal concentration of Mg2+ 
and suggests a higher affinity of the enzyme for Zn2+.  In these Zn2+-only reactions, 
HIV RT incorporated nucleotides at a maximum rate that was only 1/30th the rate of a 
Mg2+-driven reaction.  The RNase H domain of RT remained functional in Zn2+ as 
well; in a titration performed in the absence of dNTPs, the RNase H domain reached 
optimal activity at 25 µM Zn2+.   
Despite the enzyme’s poor catalytic speed in the presence of Zn2+, its 
processivity (average number of nt added in a binding event) was relatively 
undiminished.  This was due to the significantly increased stability of the enzyme-
primer-template complex when Zn2+ was present: in 2 mM Mg2+, the complex had a 
half-life of 1.7±1.0 min that increased to 220±60 min in the presence of 400 µM Zn2+.  




enabled some enzymes to complete reverse transcription of a 425 nt RNA template in 
a single binding event that lasted hours.  
These results explain the mechanism by which Zn2+ inhibits HIV RT and, by 
extension, HIV replication.  The enzyme is dramatically slowed down and synthesis 
is functionally inhibited, although the enzyme is still catalytically competent.  I 
propose a model where Zn2+ displaces Mg2+ in the catalytic cleft.  When bound to 
Zn2+, the enzyme is unable to move between catalytic states, slowing both nucleotide 
incorporation and preventing dissociation from the template.   To test if this is the 
case, it is possible to examine kon/off rates using the 65Zn isotope to directly measure 
which cation is occupying the enzyme’s metal ion binding sites under various 
conditions.  This also presents an opportunity to determine if Zn2+ binds to more than 
just the metal ion binding sites in the catalytic cleft and RNase H domain, or if it is 
able to bind to other sites on the enzyme.  If this is the case, it is possible that the 
restriction of the enzymes catalysis is due to an allosteric effect and not a direct action 
in the polymerase domain. 
Currently, our lab is investigating the effect that Zn2+ and other cations have 
on RT fidelity.  Given the profound effect that Zn2+ has on enzyme-primer-template 
complex stability and nucleotide incorporation, it is likely that the error rate of the 
enzyme will be impacted as well.   
Based off our understanding that HIV reverse transcriptase’s binding to 
primer-templates is impacted not just by the presence of different cations, but also the 
composition of the substrate, in Chapter 3 I investigated the ability of Family A DNA 




I determined that both Klenow and Taq pol had affinities for sequences that 
contained a portion of the single-subunit T7-like phage RNA polymerase promoter 
region. While this was not the only determinant of tight binding, it was an important 
factor for both enzymes.  As the single-subunit RNAPs are structurally similar to 
Family A DNA polymerases, I hypothesize that this shared affinity is either retained 
from a common ancestor or a byproduct of the homologous structures in the 
polymerase domains of the single-subunit phage RNAPs and the Family A DNA pols.   
A drawback to our method of determining the selected sequences from PT 
SELEX is that our final pool often only contains one or two sequence motifs and is a 
single snapshot in time of the evolution of sequences that lead to the final aptamers. A 
recent study by the Burke lab (136) demonstrated that using high throughput 
sequencing to monitor the populations in SELEX pools allows researchers to more 
readily identify motifs that bind tightly to the target.  Rare sequences that bind the 
target but are of too low abundance to be detected by clonal sequencing can also be 
recovered using this method.   
This is an attractive method that could potentially replace the method I 
described in Chapter 3, where I isolated sequences and performed mutational analysis 
to determine which nucleotides were important for tight binding.  The volume of data 
generated by high throughput sequencing might narrow down which nucleotides are 
potentially involved in binding and which are not, saving time and money in 
analyzing the aptamer products of selection. 
Finally, in Chapter 4 I presented two studies that began to translate research 




invasive method to recover the small molecular fraction of the cytosol for use in in 
vitro RT assays as a means to increase the accuracy of these studies relative to 
cellular RT activity.  I also began research on a method of delivering aptamers to cells 
using DNA dendrimers, which addresses a significant barrier to the use of aptamers 
as anti-retroviral therapeutics and presents an exciting next step in aptamer research. 
This work has attempted to uncover novel ways to modulate the behaviors of 
important biologically and commercially important proteins.  Knowing that the 
behavior of HIV RT can be modulated so dramatically simply by the addition of 
different divalent cations during reverse transcription raises interesting questions 
about the effect these cations play during the viral lifecycle and, worryingly, about 
the validity of some in vitro measurements taken with purified enzymes in reactions 
containing Zn2+.  If RT is so profoundly affected by the addition of non-Mg2+ divalent 
cations, even at miniscule concentrations, it will be important in the future to 
determine what (if any) affect these molecules and others have on the behavior of the 
enzyme in vivo.  Similarly, the understanding that the Family A DNA polymerases 
Klenow and Taq pol have sequence preferences for primer-templates, which they can 
bind up to 20x greater than a random substrate, suggests that these sequence 
preferences might be able to affect the behavior of these enzymes both in the context 
of the bacterial life cycle, as well as in the numerous commercial applications for 
which these enzymes are used.  These results shed light on previous unknown traits of 
HIV RT and Family A DNA polymerases, underscoring the continued need for 
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